

# UC San Diego

## UC San Diego Previously Published Works

### Title

Sex differences in neuroimmune and glial mechanisms of pain.

### Permalink

<https://escholarship.org/uc/item/42x5j3nz>

### Journal

PAIN, 162(8)

### Authors

Gregus, Ann

Levine, Ian

Eddinger, Kelly

et al.

### Publication Date

2021-08-01

### DOI

10.1097/j.pain.0000000000002215

Peer reviewed



Published in final edited form as:

*Pain*. 2021 August 01; 162(8): 2186–2200. doi:10.1097/j.pain.0000000000002215.

## Sex differences in neuroimmune and glial mechanisms of pain

Ann M. Gregus<sup>1,†</sup>, Ian S. Levine<sup>1</sup>, Kelly A. Eddinger<sup>2</sup>, Tony L. Yaksh<sup>2,3</sup>, Matthew W. Buczynski<sup>1</sup>

<sup>1</sup>School of Neuroscience, Virginia Polytechnic and State University, 970 Washington Street SW, Blacksburg, VA 24061

<sup>2</sup>Dept. of Anesthesiology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA, USA 92093-0818

<sup>3</sup>Dept. of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA, USA 92093-0601

### Keywords

dimorphism; hyperalgesia; leukocyte; glia; nociceptor; cytokine

## 1. Introduction.

### Therapeutic challenges.

The International Association for the Study of Pain (IASP) Task Force recently proposed a new definition of pain as an aversive sensory and emotional experience typically caused by, or resembling that caused by, actual or potential tissue injury [188]. Importantly, acute pain serves a critical Darwinian protective function: to initiate an escape response from noxious stimuli that in the future should be avoided for personal safety. However, chronic intractable pain is maladaptive and constitutes a widespread public health issue, significantly impairing quality of life and costing nearly \$600 billion per year in the US alone [1]. Current efforts to develop novel pain therapeutics are guided by the following observations: 1) pain may arise from multiple mechanisms, and this complexity reflects the difficulty in achieving significant relief; 2) chronic pain states may reflect an important sex covariate in the development of the pain phenotype; and 3) there is a growing appreciation that secondary to tissue and nerve injury, elements of the immune system are recruited in a sex-dependent manner to influence the chronic pain phenotype. In the following sections, we will discuss aspects of these three points.

### Categorization of pain phenotypes.

Mechanistically, pain states evolving into a chronic pain phenotype may be classified heuristically into four categories: **(1) Nociceptive pain** resulting from activation of high threshold sensory neurons (nociceptors); **(2) Inflammatory pain** resulting from persistent

<sup>†</sup>To whom correspondence should be addressed: Ann M. Gregus, Phone: (540) 231-4089, Fax: (540) 231-1475, [agregus@vt.edu](mailto:agregus@vt.edu).  
COI statement: The authors have no competing financial interests to declare.

inflammation in soft tissue (viscera, fascia, muscle), joints (arthritis), or other specific tissues (*e.g.*, dental, meningeal, bone); **(3) Neuropathic pain** resulting from direct (trauma, compression, ischemia) or indirect (chemotoxins, radiation, or autoimmune attacks, as with paraneoplastic syndromes) injury to the peripheral afferent nerve or ganglia; or **(4) Dysfunctional/Centralized pain** occurring in the absence of a noxious stimulus, detectable inflammation, or structural damage to the primary afferent [228]. It should be noted that in accord with the IASP guidelines outlined above, these four categories are associated with the generation of an aversive state accompanied by changes not only in physiology (*e.g.*, blood pressure, hormone release [42]) but also in reward and cognition (*e.g.*, formation of a negative association leading to avoidance, development of a positive appetitive response to drugs that diminish the negative affect [169]). Chronic pain syndromes with neuropathic etiology are often challenging to manage as they tend to be refractory to treatment with anti-inflammatory drugs, and many patients report inadequate or variable relief from commonly employed first-line therapies such as anticonvulsants and antidepressants [239]. While it is informative to consider types of pain individually from a mechanistic standpoint, many chronic pain conditions represent multiple phenotypes expressed simultaneously. For instance, effective management of cancer pain may require several functionally distinct medications to target various underlying processes. Furthermore, there is increasing support for the assertion that acute pain states secondary to tissue injury may evolve into a chronic condition with peripheral and central neuropathic components [183].

### **Sex as a covariate in the evolution of chronic pain.**

Evidence is accumulating in support of quantitative and qualitative sex differences in pain sensitivity and analgesia. Pain syndromes with high prevalence in humans – such as arthritis, temporomandibular disorder, migraine and fibromyalgia – disproportionately affect females, occurring with significantly greater incidence than in males [158; 194]. Such disparities largely have been attributed to genetic and hormonal differences between males and females in preclinical and clinical studies, as explored in depth by several elegant reviews [20; 53; 62; 73; 74; 158; 177]. Historically, most preclinical studies of pain hypersensitivity have focused on assessment of evoked behaviors in young adult male rats or mice. This approach largely derived from perceived challenges posed by evaluating effects of estrus cycle phases (which change every 4–5 days) on nociception and analgesic responsiveness [157]. Surprisingly, evidence suggests that variability associated with different stages of the estrus cycle is no greater than that occurring intrinsically in males [15]. There is a high failure rate of analgesic investigational new drugs in clinical trials, particularly for pain conditions with greater incidence in women [17]. Thus, elucidation of the molecular underpinnings of chronic pain states in females and the mechanisms underlying sex-dependent differences in pain signaling is critical for successful development of novel therapeutics [159]. Recent efforts are emphasizing inclusion of females and of spontaneous painful disease models such as osteoarthritis in companion animals to identify novel druggable targets for pain symptoms [111; 158], although the literature still remains biased toward males [159]. Recognizing this issue, the NIH specifically mandated that studies must employ both males and females unless there are organ-specific reasons to exclude one sex or the other. Several preclinical studies suggest that interactions between the immune and nervous systems contribute to sex differences in many chronic pain syndromes, and may serve as a source of novel drug targets

that are specific to either males, females or both [10; 40; 54; 133; 178; 195; 199; 206; 242]. In the present review, we provide a comprehensive synthesis of reported sex differences in neuroimmune mechanisms of pain hypersensitivity in rodent models, suggesting potential high-value targets to pursue for sex-specific treatments of chronic pain in men and women.

## 2. Assessment of nociception in rodent models

In humans, pain is difficult to assess reliably using objective clinical measures due to its highly subjective and individualized nature [45]. Thus, diagnosis of pain syndromes and subsequent evaluation of therapeutic efficacy relies heavily on patients' descriptions of their pain levels, features, and location. As non-verbal organisms (infants, rodents) lack this capacity, one endpoint that can be isolated and examined easily in behavioral models is nociception, or the neural process of encoding noxious stimuli constituting the sensory, non-affective component of pain (Figure 1). For excellent reviews of pain circuitry in development and adulthood, see Treede, Fitzgerald *et al.*, and Basbaum and Fields [14; 77; 223]. Injury- or disease-induced pain hypersensitivity results from peripheral or central sensitization, or the increased responsiveness of nociceptive neurons in the peripheral (PNS) and central nervous systems (CNS) to normal or subthreshold primary afferent input [122], a process mediated by several mechanisms described herein. Pain hypersensitivity presents both in humans and in animals as allodynia, wherein stimuli that do not normally produce pain are perceived as painful, or hyperalgesia, a state of enhanced sensitivity to noxious stimuli that is often coupled with spontaneous (non-evoked) pain [196]. If present at the site of injury, hyperalgesia is considered as primary, while that which occurs in the surrounding area is termed secondary. The development of secondary hyperalgesia is attributed to central sensitization.

Classically, nociception in animals is measured as nocifensive (reflexive withdrawal) behaviors in response to evoked stimuli. However, the low probability of clinical success for candidate analgesic molecules based on evoked endpoints alone has sparked efforts to improve the face validity of preclinical paradigms of chronic pain [235]. Several groups have pursued various methods of also capturing affective and motivational components of the pain state in rodents as well as in larger animals [27; 79; 96; 131; 146; 162; 171], although these approaches are still undergoing refinement. In contrast to a spinally-organized nociceptive reflex, the perception and expression of pain unpleasantness depend on higher order functions in cognitive and limbic regions of the brain (Figure 2). Since the affective component of a pain state manifests as spontaneous as well as time-, species- and paradigm-dependent behaviors, there is no singular assay in existence that encapsulates the human experience of pain in an animal. Nonetheless, some testing approaches can capture specific aspects of emotional and motivational responses to noxious stimuli. When utilized concurrently with evoked measures, these methods may provide a stronger assessment of candidate analgesic drug efficacy in preclinical pain models. For example, rodents in pain display coping behaviors such as licking the site of injury or emitting ultrasonic vocalizations [96]. Context-dependent approach or avoidance responses following injury include conditioned place aversion (CPA) to a location linked with an aversive experience (*i.e.*, a pain state) and conditioned place preference (CPP) for a site in which the pain state is alleviated [170]. Similarly, operant paradigms for self-administration of analgesic drugs

display motivated and goal-directed behaviors to obtain relief from pain [90; 93], although interpretation of the results is complicated if the drug itself is intrinsically rewarding. Since depression often is co-morbid with chronic pain, incorporation of assays of depression-like behaviors comprised of both evoked measures, such as the forced swim test, and spontaneous assessments of anhedonia, including motivation for naturally reinforcing substances like sucrose [221].

### 3. Influence of sex on evoked and spontaneous nocifensive behaviors

Several rodent models of chronic pain states exhibit sex differences that parallel findings in many human disorders, with greater sensitivity to nociceptive stimuli in females (Table 1). For example, tactile allodynia is more pronounced and/or of longer duration in female rodents in nerve injury paradigms of Chronic Constriction Injury (CCI) [226; 227] (but see also [216]), partial Sciatic Nerve Ligation (pSNL) [51], Sciatic Nerve Ligation (SNL) [32; 210; 212], Intra-Articular Lysophosphatidic Acid- (IA LPA)-induced neuropathy [174] and Endoneurial injection of functionally active Myelin Basic Protein (MBP) fragment (84–104) [40]. Hyperalgesic priming, an age-dependent model of the acute to chronic pain transition characterized by the prolongation of hyperalgesia by repeated nociceptive insults, also exhibits sexual dimorphism. This paradigm elicits increased allodynia and facial grimacing in female compared with male rodents in a dural Calcitonin Gene-Related Peptide (CGRP) model of migraine [10]. Female mice also experience earlier onset of pain-related functional deficits with systemic Lipopolysaccharide (LPS) [106], IA Complete Freund's Adjuvant (CFA)-Induced Arthritis [46], Muscle hyperalgesia [86], and Femoral Bone Cancer, correlating with faster progression of disease [64; 121]. Both mechanical and cold allodynia are more pronounced in female versus male mice in models of Multiple Sclerosis (Experimental Autoimmune Encephalitis, EAE) [185] and of Complex Regional Pain Syndrome (CRPS) [213].

In contrast, some studies report greater expression of pain hypersensitivity in males. For example, the development of allodynia following intrathecal (IT) LPS or the initiation of arthritis (K/BxN serum transfer- or intraplantar IPLT CFA-induced) is more pronounced in male mice [26; 205; 206; 242; 243], yet also see [22]. Similarly, males also exhibit increased allodynia versus females in the Spared Nerve Injury (SNI) model [97; 205; 206], yet also see [24]). The discrepancies in magnitude of allodynia reported by these studies may be explained in part by different strains of rodents or paradigms utilized. Evidence of sex differences also is emerging both in mice and in humans for the expression of cued pain-related fear memory mediated by limbic, mesolimbic, and cortical circuits [11; 153]. For example, context-dependent pain hypersensitivity is increased in males relative to females when tested by a male experimenter or when examined in an environment previously associated with an aversive tonic pain experience [145; 207].

In other injury paradigms, male and female rodents develop equivalent severity of evoked or spontaneous pain-like behaviors. Studies utilizing Collagen Antibody-Induced Arthritis (CAIA) [67], IA CFA-Induced Arthritis [66], Chemotherapy-Induced Peripheral Neuropathy (CIPN) [69], adult reincision following neonatal paw incision [165] and IPLT formalin [243] models all report allodynia of similar magnitude in males and females. Interestingly, despite

sex differences observed in allodynia during arthritis or following IT LPS, both male and female mice exhibit deficits in grip strength – a widely used rheumatology measure sensitive to analgesics and a frequently reported deficit known to correlate with pain in Rheumatoid Arthritis (RA) [106; 164]. Arthritis-induced declinations of functional measures such as locomotor activity and home cage wheel running also are observed in mice of both sexes [75; 104]. Both males and females exhibit post-surgical or arthritis injury-induced grimace behaviors as well as depressed nesting and burrowing [101; 102; 209]. Likewise, sucrose consumption and social exploration following systemic delivery of low dose LPS are transiently reduced [181] or unchanged [246] in both sexes. The effects of morphine on CPP and CPA during peripheral inflammation also are not significantly different between males and females [8; 92]. In spite of similar levels of pain-like behaviors in both sexes, it is important to note that the mechanisms underlying these behaviors sometimes differ in males versus females [26; 50; 89; 130; 149; 178; 195]. Thus, caution should be exercised when drawing conclusions about positive or negative effects of treatments for pain when males and females are not stratified [158].

### **Influence of gonadal hormones.**

Sex differences in nociceptive thresholds and opioid analgesia depend largely on organizational effects of gonadal hormone status – that is, hormone action during critical periods of gestation. Specifically, neonatal exposure to testosterone appears necessary for the phenotype of decreased nociceptive sensitivity and increased morphine analgesia observed in adult males relative to females [23; 43; 114; 117]. Nonetheless, the presence of testosterone also can exert pronociceptive actions [205]. The acute, or activational, effects of estrogens on pain and analgesia are decidedly more complex. Activational effects can vary according to the type, level, stability and route of administration of estrogens, whether they are administered alone or in combination with progestins, as well as the nociceptive paradigm utilized and the chronicity of pain state. Particular caution should be exercised in the interpretation of studies in which supraphysiological doses of these hormones are administered [52; 53].

For example, systemic administration of estradiol decreases nociceptive behaviors in the second phase (10–60 minutes post-injection) of IPLT formalin-induced acute pain in gonadectomized male or female rats [81; 115; 140] and in nerve-injured intact mice [227]. In contrast, some chronic pain states that emerge days to weeks after injury or inflammation may be exacerbated by estrogens [25; 46] or are unaffected by hormones [12]. Mu Opioid Receptor (MOR)-mediated analgesia in cycling females also depends on the phase of the estrus cycle, as morphine potency is greatest in metestrus, diestrus and proestrus phases but is lowest during estrus [107; 219]. The intricate effects of estrogens are perhaps best illustrated by the observations that estradiol suppresses the *induction* yet facilitates the *expression* of hyperalgesic priming [68; 70; 103]. By contrast, progesterone appears mainly to serve a protective function, in that it mediates pregnancy-related analgesia [192] and attenuates hyperalgesia precipitated by IPLT CFA- or Carrageenan-induced monoarthritis [189; 214], excitotoxic spinal cord injury [84] and Peripheral Diabetic Neuropathy (PDN) [126]. For in-depth discussions of these processes, the reader is directed to several extensive reviews [20; 47; 52; 105; 147; 158; 234].

### **Influence of stress pathways.**

Similarly, stress also exerts paradoxical analgesic and hyperalgesic effects that are sexually dimorphic and likely are mediated by estradiol and testosterone [99] as well as stress hormones of the Hypothalamic Pituitary Adrenal (HPA) axis such as Corticotrophin Releasing Factor (CRF), Adrenocorticotrophic Hormone (ACTH), and glucocorticoids [80; 132]. Interestingly, antisense knockdown of spinal  $\beta 2$  adrenergic receptors attenuates CIPN in female but not male rats, while the inverse is observed following knockdown of spinal glucocorticoid receptors [69]. Following early life stress, female rats exhibit increased central amygdala CRF-mediated visceral pain hypersensitivity [184] and augmented expression of hippocampal Tumor Necrosis Factor alpha (TNF $\alpha$ ) and IL-6 concomitant with greater SNL-induced allodynia [32]. These findings indicate sex-specific dependence on stress mediators of the sympathetic nervous system and the HPA axis in addition to gonadal hormones.

### **Influence of genetics.**

In a rodent model of lumbar L5 radiculopathy, female Sprague-Dawley and Long-Evans but not Holtzman rats developed more severe mechanical allodynia than their male counterparts [116]. These findings are corroborated by the observation that L5 spinal nerve transection (SNT) produced greater allodynia in female versus male Sprague-Dawley rats, but no significant sex difference in Holtzman rats [57]. Swim stress-induced analgesia (SIA) is greater in female Wistar and Spontaneously Hypertensive (SHR) but not Lewis rats [230]. In contrast, SIA is enhanced in male C57BL/6 and Swiss Webster mice compared with isogenic females [160]. Similarly, morphine antinociception also is greater in several strains of male rats and mice, as reviewed in depth [161]. While allodynia is expressed in both sexes of CD-1 mice, it is evident in male but not female C57BL/6 mice in the destabilization of the medial meniscus (DMM) model of knee osteoarthritis (OA) [139]. Of note, substrain differences of C57BL/6J versus C57BL/6N mice in nociceptive behaviors are found following IPLT formalin, but not with IPLT CFA or CCI models [28]. QTL mapping in a cross of these strains uncovered a difference between B6J versus B6N, with thermal nociception being more pronounced in males. These observations indicate that rodent strain also should be considered when drawing conclusions about sex differences in pain hypersensitivity.

## **4. Sex-dependent neuroimmune mechanisms of pain hypersensitivity**

Tissue damage or infection initiates an immune response that can ultimately lead to a chronic pain state. Acute inflammation serves a dual purpose in that a wide variety of mediators are secreted to prevent the organism from incurring further injury and to recruit peripheral immune cells for containing and repairing the damage. Historically, these factors have been characterized as either maladaptive “pro-inflammatory” or beneficial “pro-resolving”, and are released sequentially to promote active healing. Our current understanding of pathogen- or damage associated molecular pattern-induced inflammatory responses may best be described as an organized progression of interactions between immune cells. Accordingly, the secretion of factors by each cell type influences the timing and destination of chemotaxis by another cell type [19; 29; 82]. Under typical



circumstances, pain remains acute as the injury is repaired and inflammation is resolved, allowing the organism to resume homeostasis.

It is widely recognized that infiltrating as well as resident immune cells likely contribute to the transition from acute to chronic pain in instances where either the damage cannot be repaired or dysregulated inflammatory signaling continues even after the injury is resolved (see Figure 3 for definitions of immune cell types) [13]. For example, infiltrating neutrophils, macrophages and T-lymphocytes as well as activated Schwann cells and satellite cells secrete factors to communicate with resident astrocytes, microglia and oligodendrocytes in the CNS to release mediators that sensitize nociceptors. These processes in turn trigger adjacent glia and neurons to drive maintenance of hyperalgesia and allodynia [31; 98; 148; 155; 198; 200; 231; 247]. Among the molecules contributing to central sensitization are neurotransmitters (glutamate, ATP), peptide signals (cytokines, chemokines, neuropeptides), and bioactive lipids generated from cyclooxygenases (COX-1/2), 12/15-Lipoxygenases (12/15-LOX), and endocannabinoid system enzymes [87; 88; 108; 138; 236; 237; 241].

Emerging evidence supports a profound role for sex-specific immune responses that may underlie disparities in incidence of pain and other neurological disorders [18; 60; 62; 141; 186; 191; 208]. Due to specific challenges unique to each sex, the male and female immune systems have different requirements, with the female immune system specifically requiring the flexibility to allow for pregnancy without attacking the fetus or sperm required for procreation [187]. Consequently, females have larger populations of most immune cells, higher levels of immunoglobulins, and exhibit stronger responses to infection [110; 168]. Conversely in males, the Y chromosome contains multiple genes involved in epigenetic regulation of the immune system and susceptibility to autoimmune diseases [37]. While some neuroimmune interactions underly nociceptive processing in both males and females, some pain states exhibit clear sex-specific mechanisms that likely affect their responsiveness to current analgesics and adjuvant therapeutics [9].

### **Male-specific nociceptive mechanisms.**

Chronification of pain states in males is believed to be facilitated largely by the innate immune system through neutrophil recruitment to the injury site [197] and to the spinal vasculature [156], along with CNS infiltration of monocytes and activation of microglial-neuronal crosstalk via several mechanisms [179] (Table 2). While significant spinal microgliosis is evident in both sexes of rodents following injury [3; 38; 206; 242], allodynia in males is believed to be mediated by several mechanisms including, but not limited to: stimulation of purinergic P2X4 receptors [142; 224] likely on CX3CR1- (Fractalkine receptor)-positive microglia [224; 248], phosphorylation of P38 Mitogen-Activated Protein (MAP) Kinase [100; 137; 165; 216] and release of cytokines such as Brain-Derived Neurotrophic Factor (BDNF) either from spinal microglia [206] or Dorsal Root Ganglion (DRG) nociceptors [166], acting on Tropomyosin receptor kinase B (TrkB) receptors in spinal dorsal horn neurons. In a model of pain chronification, hyperalgesic priming with IT BDNF or IPLT Interleukin 6 (IL-6) is mediated by activation of spinal Dopamine D5 receptors (DRD5) in male but not female spinal neurons [149]. Furthermore, the NOD-like Receptor 3



(NLRP3) inflammasome drives IL-1 $\beta$  release likely from non-neuronal cells, leading to subsequent activation of neuronal Transient Receptor Potential Ankyrin 1 (TRPA1) in males but not females in a postoperative pain model of paw incision [50]. Likewise, in CCI or SNT paradigms of neuropathic pain, the cytokine TNF $\alpha$  mediates allodynia via spinal TNF Receptor 1 (TNFR1) only in male mice despite similar expression of allodynia in both sexes [56; 211]. TNF $\alpha$  and IL-1 $\beta$  are unchanged supraspinally in anterior cingulate cortex (ACC) following common peroneal nerve injury, indicating potential local release and site-specific involvement of these mediators. However, these studies were performed in a mixed-sex cohort of mice [135].

Thus, it is important to consider that male-specific involvement of macrophages and neuroimmune mediators in allodynia is likely dependent on the paradigm utilized, the activation of specific circuits (spinal versus supraspinal), hormone status, or be influenced by other factors such as age [94; 95; 129; 134] and strain [152; 202]. Injury-induced activation of Toll-Like Receptor 4 (TLR4) is a prominent example of this controversy. IT delivery of LPS or endogenous ligands (*e.g.*, High Mobility Group Box 1, HMGB1) and models of Peripheral neuropathy or RA elicit spinal TLR4-dependent allodynia that in some, but not all, cases is more pronounced in males than in females [2; 195; 205; 206; 240; 242; 243]. The observed reduction in responsiveness of females to spinal TLR4 activation appears to be dependent on estrogen, as ovariectomy in conjunction with testosterone replacement restores expression of TLR4-mediated allodynia in CD-1 female mice to levels comparable to that observed in intact males [205]. Estrogen also attenuates LPS-induced inflammatory signaling and prevents expression of the proinflammatory phenotype of microglia during development [229; 232; 233]. Interestingly, the sex difference observed in spinal TLR4-mediated allodynia is absent when LPS is administered either at supraspinal (intracerebroventricular, ICV) or peripheral (IPLT) sites in uninjured CD-1 mice [205], or intramuscularly (IM) in a model of non-inflammatory acidic saline-induced muscle hyperalgesia [83]. In addition, systemic delivery of LPS produces pain hypersensitivity in both male and female Sprague-Dawley rats as neonates and as adults [21], correlating with decreased expression of *Oprm1* encoding MOR in the Periaqueductal Gray (PAG) [246] and IL-1 $\beta$  mRNA in the spinal cord, ventrolateral PAG and hippocampus [182]. These observations are consistent with the finding that intra-PAG LPS in rats significantly decreases morphine antinociception in both sexes [61]. Similarly, in both sexes of C57BL/6 mice, IPLT formalin-induced delayed tactile hypersensitivity is prevented by global deletion of TLR4 [243], and spinal blockade of HMGB1 reverses CAIA-induced mechanical allodynia [2].

Furthermore, in some paradigms, crosstalk between macrophages and sensory neurons contributes to allodynia in both sexes (Table 3). For example, IPLT Angiotensin II activates its receptors (AT2R) in peripheral Iba1(+) leukocytes, leading to TRPA1 transactivation in nociceptors concurrent with pain hypersensitivity in males and females [199]. IT delivery of BDNF elicits allodynia in both sexes of CD-1 mice [143], while IL-6 contributes to enhanced hyperalgesia in males and females following muscle injury [83] and peripheral inflammation [83; 217]. In a model of hyperalgesic priming for migraine, intracisternal (IC) IL-6-induced dural inflammation is BDNF-dependent in both male and female Sprague-Dawley rats [30]. K/BxN arthritis elicits time-dependent increases in spinal and circulating

TNF $\alpha$  in males and females, and IPLT delivery of TNF $\alpha$  produces spinal Transient Receptor Potential Vanilloid 1- (TRPV1)-dependent allodynia in both sexes [22; 66].

### Female-specific nociceptive mechanisms.

Sustained allodynia in females is thought to derive in part from the adaptive immune system via activation and infiltration of Cluster of Differentiation 4 (CD4)<sup>+</sup> T-lymphocytes to either central [206] or peripheral sites following nerve injury [91; 133] (Table 2). Interestingly, intra-sciatic (IS) injection of MBP(84–104) elicits T-cell migration to the DRG and spinal cord concurrent with tactile allodynia in female but not in male mice, in which T cells remain localized to the sciatic nerve [40]. Voluntary wheel running attenuates EAE-induced allodynia, correlating with reduced release of inflammatory cytokines from myelin-reactive T cells and attenuated DRG neuron excitability in female but not in male mice [154]. However, a female-specific role of the adaptive immune system remains to be clarified and may be paradigm- or strain-dependent. Several investigators have demonstrated that infiltrating CD4<sup>+</sup> T-cells also contribute to tactile hypersensitivity following SNT or SNI in male Balb/c or C57BL/6 mice and Sprague-Dawley rats, respectively [34–36; 44; 49]. CD4<sup>+</sup> T-cells mediate reduced formalin-mediated nociceptive sensitivity and increased morphine analgesia in male compared with female CD-1 mice [193]. In addition, T regulatory cells (Tregs) are essential for recovery from CCI-induced tactile allodynia via TNF $\alpha$  Receptor 2 (TNFR2) in both sexes [76].

Alternatively, other immune cells may be involved in female-specific mechanisms of neuropathic pain, as the number of mast cells is increased in lumbar spinal dura mater during Intradermal (ID) Capsaicin- or IPLT Carrageenan-induced inflammation [244] as well as on the side of the thalamus receiving nociceptive input following SNL [212], concurrent with allodynia in female but not in male rodents. Mast cells also mediate ID nitroglycerin-induced hyperalgesia, which is more pronounced in female rats [71]. However, paw incision- or CFA-induced activation of the mast cell receptor Mas-Related G Protein-Coupled Receptor b2 (Mrgprb2) elicits inflammation and pain hypersensitivity that is not different between male and female mice [85], so a female-specific involvement of mast cells may depend on the pain model utilized.

Microglia are believed to drive allodynia predominantly in males, yet several reports suggest that females can switch to a microglia-dependent pathway in some models of pain hypersensitivity when adaptive immune mechanisms are suppressed [89; 205; 206]. For example, microglial P2X7 is activated in females during IA Carrageenan- or Collagen-Induced Arthritis (CIA) [173; 218] yet not following IPLT CFA monoarthritis or pSNL- or SNI-induced nerve injury [41; 54]. Female-specific progesterone-dependent upregulation of Neuregulin-1 (NRG-1) in astrocytes has been observed in a model of experimental L5 lumbar radiculopathy, while exogenous spinal delivery of NRG-1 produces allodynia in both sexes [118; 119]. Mice heterozygous for NRG-1 express sex-specific reductions in serum cytokines in conjunction with increased hotplate latency, including IL-6, IL-8 and IL-10 in females and IL-1 $\beta$  in males [58]. However, IL-6 may also exert a female-specific protective effect, as female IL-6 deficient mice experience increased autotomy behavior following nerve injury [245]. Other mechanisms of nociception in females include inflammation-

induced activation of CNS DRD3 [130] or DRD1 receptors [149], Gamma Aminobutyric Acid Receptor subtype A (GABA<sub>A</sub>) in the PAG [222] or spinal cord [78], and Prolactin receptors (PRLR) in sensory neurons [39; 178].

## 5. Future directions

Chronic pain affects up to 33% of the population and surpasses cancer, diabetes and heart disease in terms of societal burden [59]. Management of persistent pain is largely an exercise of trial and error, and the scarcity of viable treatment options places undue burden on the patient [183]. There is a considerable body of evidence demonstrating that an interaction between the nervous and immune systems underlies many pain syndromes at the molecular and cellular level. Since immune cells play a major role in the development of mood disorders [151], it is likely that they also may contribute to the aversive emotional experience of pain. Most clinically relevant pain states have a tonic component that is not captured by standard evoked paradigms, so continued incorporation of spontaneous and functional measures of pain behaviors in preclinical studies will be critical for a deeper understanding of sex-related differences in chronic pain states and the future development of analgesics [109; 169; 171; 215]. Taken together, studies suggest that neuroimmune signaling events altered by injury, disease, or aberrant central nociceptive processing may serve as a rich resource of novel druggable targets and of predictive biomarkers suitable for patient stratification in trials [55] examining efficacy of potential pain therapeutics.

Given the challenges of developing safe and effective drugs reaching the CNS [201], one potential therapeutic avenue is to neutralize release of cytokines and chemokines released from circulating leukocytes and/or to intercept these cells before they cross the blood-brain barrier (BBB). Accordingly, the development of monoclonal antibody-based interventions targeting immune system mediators for the treatment of cancer and autoimmune diseases has grown exponentially over the past decade [136]. As our understanding of the role of specific immune cells in the development and maintenance of central sensitization continues to evolve, some of the newer-generation FDA-approved biologics may be repurposed for treating chronic pain either of peripheral origin via systemic delivery, or by routes of administration that bypass the BBB (*e.g.* intranasal or intrathecal). Alternatively, humanized single-domain antibodies could be harnessed as therapeutics, diagnostic agents or as delivery devices of small molecules targeting specific leukocytes owing to their stability, small size and low production cost [16]. Nonetheless, small molecules still lead the field in percent of FDA approvals in spite of challenges encountered with safety and tolerability profiles [167]. Ultimately, it is imperative for more preclinical and clinical pain studies to draw direct comparisons between males and females. Including sex as a biological variable will allow experts both to better predict which therapeutic strategies may be effective in each sex and to achieve true progress in the discovery of novel non-opioid analgesics.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments.

This work was supported by NIH AR075241 (AMG); Cayman Biomedical Research Institute (CABRI) Undergraduate Research Award (ISL); NIH NS099338 and DA015353 (TLY); NIH DA035865 (MWB).

## Abbreviations

<b>AT2R</b>	Angiotensin 2 Receptor
<b>BDNF</b>	Brain-Derived Neurotrophic Factor
<b>CGRP</b>	Calcitonin Gene-Related Peptide
<b>S100A8</b>	Calgranulin
<b>S100A9</b>	Calgranulin B
<b>CIPN</b>	Chemotherapy-induced Peripheral Neuropathy
<b>CCI</b>	Chronic Constriction Injury
<b>Cd11b</b>	Cluster of Differentiation 11b
<b>CD14</b>	Cluster of Differentiation 14
<b>CD2</b>	Cluster of Differentiation 2
<b>CD4</b>	Cluster of Differentiation 4
<b>CD40</b>	Cluster of Differentiation 40
<b>CD68</b>	Cluster of Differentiation 68
<b>CD8</b>	Cluster of Differentiation 8
<b>CAIA</b>	Collagen Antibody-Induced Arthritis
<b>CFA</b>	Complete Freund's Adjuvant
<b>CRPS</b>	Complex Regional Pain Syndrome
<b>COX2</b>	Cyclooxygenase 2
<b>DMM</b>	Destabilization of Medial Meniscus
<b>dsHMGB1</b>	disulfide High Mobility Group Box 1
<b>DRD1</b>	Dopamine Receptor D1
<b>DRD3</b>	Dopamine Receptor D3
<b>DRD5</b>	Dopamine Receptor D5
<b>DRG</b>	Dorsal Root Ganglion

<b>ErbB</b>	Epidermal Growth Factor receptor tyrosine-protein kinase erbB-2
<b>ErbB4</b>	Erb-B2 Receptor Tyrosine Kinase 4
<b>EAE</b>	Experimental Autoimmune Encephalomyelitis
<b>CX3CR1</b>	Fractalkine Receptor
<b>GABA<sub>A</sub></b>	Gamma Amino Butyric Acid receptor subtype A
<b>Oprm1</b>	Mu Opioid Receptor gene
<b>GFAP</b>	Glial Fibrillary Acidic Protein
<b>CXCL1 = Gro<math>\alpha</math></b>	Growth Related Oncogene alpha
<b>HMGB1</b>	High Mobility Group Box 1
<b>IL-1<math>\beta</math></b>	Interleukin 1 beta
<b>IL-6</b>	Interleukin 6
<b>IA</b>	Intra-Articular
<b>IC</b>	Intracisternal
<b>ICV</b>	Intracerebroventricular
<b>ID</b>	Intradermal
<b>IM</b>	Intramuscular
<b>IP</b>	Intraperitoneal
<b>IPLT</b>	Intraplantar
<b>IT</b>	Intrathecal
<b>LPS</b>	Lipopolysaccharide
<b>Ly6G</b>	Lymphocyte antigen 6 complex locus G6D
<b>LPA</b>	Lysophosphatidic Acid
<b>CXCL2</b>	MIP2 $\alpha$ : Macrophage Inflammatory Protein 2 alpha
<b>MAPK</b>	Mitogen-Activated Protein Kinase
<b>Mrgbr2</b>	Mas-Related G protein-Coupled Receptor B2
<b>MCP1 = CCL2</b>	Monocyte Chemoattractant Protein 1
<b>MBP</b>	Myelin Basic Protein
<b>NRG-1</b>	Neuregulin-1

<b>NK1</b>	Neurokinin receptor 1
<b>NMDAR1</b>	N-methyl D-Aspartate Receptor 1
<b>NLRP3</b>	Nod-Like Receptor Protein 3
<b>P2X2</b>	P2X purinoceptor 2
<b>P2X3</b>	P2X purinoceptor 3
<b>P2X4</b>	P2X purinoceptor 4
<b>P2X7</b>	P2X purinoceptor 7
<b>pSNL</b>	partial Sciatic Nerve Ligation
<b>PAG</b>	Periaqueductal Gray
<b>KCC2</b>	Potassium-chloride transporter member 5
<b>PFC</b>	Prefrontal Cortex
<b>PRLR</b>	Prolactin Receptor
<b>RAMP1</b>	Receptor Activity Modification Protein 1
<b>SNP</b>	Sodium Nitroprusside
<b>SNI</b>	Spared Nerve Injury
<b>SNL</b>	Spinal Nerve Ligation
<b>SNT</b>	Spinal Nerve Transection
<b>TAC1</b>	Tachykinin Precursor 1
<b>TLR4</b>	Toll-Like Receptor 4
<b>TRPA1</b>	Transient Receptor Potential Ankyrin 1
<b>TRPV1</b>	Transient Receptor Potential Vanilloid 1
<b>TNF<math>\alpha</math></b>	Tumor Necrosis Factor alpha
<b>TNFR1</b>	Tumor Necrosis Factor Receptor 1
<b>TNFR2</b>	Tumor Necrosis Factor Receptor 2

## References.

- [1]. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. *Military medicine* 2016;181(5):397–399. [PubMed: 27136641]
- [2]. Agalave NM, Larsson M, Abdelmoaty S, Su J, Baharpoor A, Lundback P, Palmblad K, Andersson U, Harris H, Svensson CI. Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. *Pain* 2014;155(9):1802–1813. [PubMed: 24954167]

- [3]. Agalave NM, Rudjito R, Farinotti AB, Khoonsari PE, Sandor K, Nomura Y, Szabo-Pardi TA, Urbina CM, Palada V, Price TJ, Harris HE, Burton MD, Kultima K, Svensson CI. Sex-dependent role of microglia in disulfide HMGB1-mediated mechanical hypersensitivity. *Pain* 2020.
- [4]. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. *Nature reviews Immunology* 2020;20(4):229–238.
- [5]. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. *Brain research* 2004;1000(1–2):40–56. [PubMed: 15053950]
- [6]. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. *Nature reviews Immunology* 2006;6(3):205–217.
- [7]. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. *Nature reviews Immunology* 2015;15(1):7–17.
- [8]. Armendariz A, Nazarian A. Morphine antinociception on thermal sensitivity and place conditioning in male and female rats treated with intraplantar complete freund's adjuvant. *Behavioural brain research* 2018;343:21–27. [PubMed: 29378294]
- [9]. Averitt DL, Eidson LN, Doyle HH, Murphy AZ. Neuronal and glial factors contributing to sex differences in opioid modulation of pain. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2019;44(1):155–165. [PubMed: 29973654]
- [10]. Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G. Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2019;39(22):4323–4331. [PubMed: 30962278]
- [11]. Baliki MN, Apkarian AV. Nociception, Pain, Negative Moods, and Behavior Selection. *Neuron* 2015;87(3):474–491. [PubMed: 26247858]
- [12]. Banik RK, Woo YC, Park SS, Brennan TJ. Strain and sex influence on pain sensitivity after plantar incision in the mouse. *Anesthesiology* 2006;105(6):1246–1253. [PubMed: 17122588]
- [13]. Baral P, Udit S, Chiu IM. Pain and immunity: implications for host defence. *Nature reviews Immunology* 2019;19(7):433–447.
- [14]. Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. *Annals of neurology* 1978;4(5):451–462. [PubMed: 216303]
- [15]. Beery AK. Inclusion of females does not increase variability in rodent research studies. *Curr Opin Behav Sci* 2018;23:143–149. [PubMed: 30560152]
- [16]. Belanger K, Iqbal U, Tanha J, MacKenzie R, Moreno M, Stanimirovic D. Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. *Antibodies (Basel)* 2019;8(2).
- [17]. Berge OG. Predictive validity of behavioural animal models for chronic pain. *British journal of pharmacology* 2011;164(4):1195–1206. [PubMed: 21371010]
- [18]. Berta T, Qadri YJ, Chen G, Ji RR. Microglial Signaling in Chronic Pain with a Special Focus on Caspase 6, p38 MAP Kinase, and Sex Dependence. *Journal of dental research* 2016;95(10):1124–1131. [PubMed: 27307048]
- [19]. Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. *The Journal of biological chemistry* 2009;284(32):21599–21612. [PubMed: 19487688]
- [20]. Bodnar RJ, Kest B. Sex differences in opioid analgesia, hyperalgesia, tolerance and withdrawal: central mechanisms of action and roles of gonadal hormones. *Horm Behav* 2010;58(1):72–81. [PubMed: 19786031]
- [21]. Boisse L, Spencer SJ, Mouihate A, Vergnolle N, Pittman QJ. Neonatal immune challenge alters nociception in the adult rat. *Pain* 2005;119(1–3):133–141. [PubMed: 16297551]
- [22]. Borbely E, Botz B, Bolcskei K, Kenyer T, Kereskai L, Kiss T, Szolcsanyi J, Pinter E, Csepregi JZ, Mocsai A, Helyes Z. Capsaicin-sensitive sensory nerves exert complex regulatory functions in the serum-transfer mouse model of autoimmune arthritis. *Brain, behavior, and immunity* 2015;45:50–59.
- [23]. Borzan J, Fuchs PN. Organizational and activational effects of testosterone on carrageenan-induced inflammatory pain and morphine analgesia. *Neuroscience* 2006;143(3):885–893. [PubMed: 17008018]



- [24]. Bourquin AF, Suveges M, Pertin M, Gilliard N, Sardy S, Davison AC, Spahn DR, Decosterd I. Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. *Pain* 2006;122(1–2):14 e11–14. [PubMed: 16542774]
- [25]. Bradshaw H, Miller J, Ling Q, Malsnee K, Ruda MA. Sex differences and phases of the estrous cycle alter the response of spinal cord dynorphin neurons to peripheral inflammation and hyperalgesia. *Pain* 2000;85(1–2):93–99. [PubMed: 10692607]
- [26]. Britch SC, Goodman AG, Wiley JL, Pondelick AM, Craft RM. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain. *The Journal of pharmacology and experimental therapeutics* 2020;373(3):416–428. [PubMed: 32179573]
- [27]. Browne LE, Latremoliere A, Lehnert BP, Grantham A, Ward C, Alexandre C, Costigan M, Michoud F, Roberson DP, Ginty DD, Woolf CJ. Time-Resolved Fast Mammalian Behavior Reveals the Complexity of Protective Pain Responses. *Cell reports* 2017;20(1):89–98. [PubMed: 28683326]
- [28]. Bryant CD, Bagdas D, Goldberg LR, Khalefa T, Reed ER, Kirkpatrick SL, Kelliher JC, Chen MM, Johnson WE, Mulligan MK, Imad Damaj M. C57BL/6 substrain differences in inflammatory and neuropathic nociception and genetic mapping of a major quantitative trait locus underlying acute thermal nociception. *Molecular pain* 2019;15:1744806918825046. [PubMed: 30632432]
- [29]. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. *Nature reviews Immunology* 2013;13(1):59–66.
- [30]. Burgos-Vega CC, Quigley LD, Avona A, Price T, Dussor G. Dural stimulation in rats causes brain-derived neurotrophic factor-dependent priming to subthreshold stimuli including a migraine trigger. *Pain* 2016;157(12):2722–2730. [PubMed: 27841839]
- [31]. Burke NN, Fan CY, Trang T. Microglia in health and pain: impact of noxious early life events. *Exp Physiol* 2016;101(8):1003–1021. [PubMed: 27474262]
- [32]. Burke NN, Llorente R, Marco EM, Tong K, Finn DP, Viveros MP, Roche M. Maternal deprivation is associated with sex-dependent alterations in nociceptive behavior and neuroinflammatory mediators in the rat following peripheral nerve injury. *The journal of pain : official journal of the American Pain Society* 2013;14(10):1173–1184.
- [33]. Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. *Nat Rev Neurosci* 2013;14(7):502–511. [PubMed: 23719569]
- [34]. Cao L, Beaulac H, Eurich A. Differential lumbar spinal cord responses among wild type, CD4 knockout, and CD40 knockout mice in spinal nerve L5 transection-induced neuropathic pain. *Molecular pain* 2012;8:88. [PubMed: 23249743]
- [35]. Cao L, DeLeo JA. CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. *European journal of immunology* 2008;38(2):448–458. [PubMed: 18196515]
- [36]. Cao L, Palmer CD, Malon JT, De Leo JA. Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain. *European journal of immunology* 2009;39(12):3562–3569. [PubMed: 19750482]
- [37]. Case LK, Wall EH, Dragon JA, Saligrama N, Kremontsov DN, Moussawi M, Zachary JF, Huber SA, Blankenhorn EP, Teuscher C. The Y chromosome as a regulatory element shaping immune cell transcriptomes and susceptibility to autoimmune disease. *Genome Res* 2013;23(9):1474–1485. [PubMed: 23800453]
- [38]. Chen G, Luo X, Qadri MY, Berta T, Ji RR. Sex-Dependent Glial Signaling in Pathological Pain: Distinct Roles of Spinal Microglia and Astrocytes. *Neuroscience bulletin* 2018;34(1):98–108. [PubMed: 28585113]
- [39]. Chen Y, Moutal A, Navratilova E, Kopruszinski C, Yue X, Ikegami M, Chow M, Kanazawa I, Bellampalli SS, Xie J, Patwardhan A, Rice K, Fields H, Akopian A, Neugebauer V, Dodick D, Khanna R, Porreca F. The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. *Science translational medicine* 2020;12(529).
- [40]. Chernov AV, Hullugundi SK, Eddinger KA, Dolkas J, Remacle AG, Angert M, James BP, Yaksh TL, Strongin AY, Shubayev VI. A myelin basic protein fragment induces sexually dimorphic

transcriptome signatures of neuropathic pain in mice. *The Journal of biological chemistry* 2020;295(31):10807–10821. [PubMed: 32532796]

- [41]. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. *Pain* 2005;114(3):386–396. [PubMed: 15777864]
- [42]. Chiang MC, Bowen A, Schier LA, Tupone D, Uddin O, Heinricher MM. Parabrachial Complex: A Hub for Pain and Aversion. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2019;39(42):8225–8230. [PubMed: 31619491]
- [43]. Cicero TJ, Nock B, O'Connor L, Meyer ER. Role of steroids in sex differences in morphine-induced analgesia: activational and organizational effects. *The Journal of pharmacology and experimental therapeutics* 2002;300(2):695–701. [PubMed: 11805235]
- [44]. Cobos EJ, Nickerson CA, Gao F, Chandran V, Bravo-Caparros I, Gonzalez-Cano R, Riva P, Andrews NA, Latremoliere A, Seehus CR, Perazzoli G, Nieto FR, Joller N, Painter MW, Ma CHE, Omura T, Chesler EJ, Geschwind DH, Coppola G, Rangachari M, Woolf CJ, Costigan M. Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling. *Cell reports* 2018;22(5):1301–1312. [PubMed: 29386116]
- [45]. Coghill RC, McHaffie JG, Yen YF. Neural correlates of interindividual differences in the subjective experience of pain. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100(14):8538–8542. [PubMed: 12824463]
- [46]. Cook CD, Nickerson MD. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats. *The Journal of pharmacology and experimental therapeutics* 2005;313(1):449–459. [PubMed: 15608071]
- [47]. Coraggio V, Guida F, Boccella S, Scafuro M, Paino S, Romano D, Maione S, Luongo L. Neuroimmune-Driven Neuropathic Pain Establishment: A Focus on Gender Differences. *International journal of molecular sciences* 2018;19(1).
- [48]. Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and Exogenous Opioids in Pain. *Annu Rev Neurosci* 2018;41:453–473. [PubMed: 29852083]
- [49]. Costigan M, Moss A, Latremoliere A, Johnston C, Verma-Gandhu M, Herbert TA, Barrett L, Brenner GJ, Vardeh D, Woolf CJ, Fitzgerald M. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2009;29(46):14415–14422. [PubMed: 19923276]
- [50]. Cowie AM, Menzel AD, O'Hara C, Lawlor MW, Stucky CL. NOD-like receptor protein 3 inflammasome drives postoperative mechanical pain in a sex-dependent manner. *Pain* 2019;160(8):1794–1816. [PubMed: 31335648]
- [51]. Coyle DE, Sehlhorst CS, Mascari C. Female rats are more susceptible to the development of neuropathic pain using the partial sciatic nerve ligation (PSNL) model. *Neuroscience letters* 1995;186(2–3):135–138. [PubMed: 7777182]
- [52]. Craft RM. Modulation of pain by estrogens. *Pain* 2007;132 Suppl 1:S3–12. [PubMed: 17951003]
- [53]. Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: the role of gonadal hormones. *European journal of pain (London, England)* 2004;8(5):397–411.
- [54]. Dalgarno R, Leduc-Pessah H, Pilapil A, Kwok CH, Trang T. Intrathecal delivery of a palmitoylated peptide targeting Y382–384 within the P2X7 receptor alleviates neuropathic pain. *Molecular pain* 2018;14:1744806918795793. [PubMed: 30146934]
- [55]. Davis KD, Aghaepour N, Ahn AH, Angst MS, Borsook D, Brenton A, Burczynski ME, Crean C, Edwards R, Gaudilliere B, Hergenroeder GW, Iadarola MJ, Iyengar S, Jiang Y, Kong JT, Mackey S, Saab CY, Sang CN, Scholz J, Segerdahl M, Tracey I, Veasley C, Wang J, Wager TD, Wasan AD, Pellemounter MA. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. *Nat Rev Neurol* 2020;16(7):381–400.
- [56]. Del Rivero T, Fischer R, Yang F, Swanson KA, Bethea JR. Tumor necrosis factor receptor 1 inhibition is therapeutic for neuropathic pain in males but not in females. *Pain* 2019;160(4):922–931. [PubMed: 30586024]

- [57]. DeLeo JA, Rutkowski MD. Gender differences in rat neuropathic pain sensitivity is dependent on strain. *Neuroscience letters* 2000;282(3):197–199. [PubMed: 10717425]
- [58]. Desbonnet L, Cox R, Tighe O, Lai D, Harvey RP, Waddington JL, O’Tuathaigh CM. Altered cytokine profile, pain sensitivity, and stress responsivity in mice with co-disruption of the developmental genes Neuregulin-1xDISC1. *Behavioural brain research* 2017;320:113–118. [PubMed: 27916686]
- [59]. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet (London, England)* 2018;392(10159):1789–1858.
- [60]. Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2018;43(1):52–79. [PubMed: 28857069]
- [61]. Doyle HH, Eidson LN, Sinkiewicz DM, Murphy AZ. Sex Differences in Microglia Activity within the Periaqueductal Gray of the Rat: A Potential Mechanism Driving the Dimorphic Effects of Morphine. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2017;37(12):3202–3214. [PubMed: 28219988]
- [62]. Doyle HH, Murphy AZ. Sex differences in innate immunity and its impact on opioid pharmacology. *Journal of neuroscience research* 2017;95(1–2):487–499. [PubMed: 27870418]
- [63]. Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. *The Journal of clinical investigation* 2010;120(11):3760–3772. [PubMed: 21041958]
- [64]. Falk S, Uldall M, Appel C, Ding M, Heegaard AM. Influence of sex differences on the progression of cancer-induced bone pain. *Anticancer research* 2013;33(5):1963–1969. [PubMed: 23645744]
- [65]. Farber DL. Form and function for T cells in health and disease. *Nature reviews Immunology* 2020;20(2):83–84.
- [66]. Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R, Gentry C, Staniland AA, Mountford DM, Keeble JE, Malcangio M, Bevan S, Brain SD. A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and Freund’s complete adjuvant-induced monoarthritis. *Arthritis and rheumatism* 2011;63(3):819–829. [PubMed: 21360511]
- [67]. Fernandez-Zafra T, Gao T, Jurczak A, Sandor K, Hore Z, Agalave NM, Su J, Estelius J, Lampa J, Hokfelt T, Wiesenfeld-Hallin Z, Xu X, Denk F, Svensson CI. Exploring the transcriptome of resident spinal microglia after collagen antibody-induced arthritis. *Pain* 2019;160(1):224–236. [PubMed: 30247264]
- [68]. Ferrari LF, Araldi D, Green P, Levine JD. Age-Dependent Sexual Dimorphism in Susceptibility to Develop Chronic Pain in the Rat. *Neuroscience* 2018;387:170–177. [PubMed: 28676241]
- [69]. Ferrari LF, Araldi D, Green PG, Levine JD. Marked sexual dimorphism in neuroendocrine mechanisms for the exacerbation of paclitaxel-induced painful peripheral neuropathy by stress. *Pain* 2020;161(4):865–874. [PubMed: 31917777]
- [70]. Ferrari LF, Araldi D, Levine JD. Regulation of Expression of Hyperalgesic Priming by Estrogen Receptor alpha in the Rat. *The journal of pain : official journal of the American Pain Society* 2017;18(5):574–582.
- [71]. Ferrari LF, Levine JD, Green PG. Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat. *Neuroscience* 2016;317:121–129. [PubMed: 26779834]
- [72]. Ferretti E, Hadjantonakis AK. Mesoderm specification and diversification: from single cells to emergent tissues. *Curr Opin Cell Biol* 2019;61:110–116. [PubMed: 31476530]
- [73]. Fillingim RB, Gear RW. Sex differences in opioid analgesia: clinical and experimental findings. *European journal of pain (London, England)* 2004;8(5):413–425.
- [74]. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. *The journal of pain : official journal of the American Pain Society* 2009;10(5):447–485.

- [75]. Fischer BD, Adeyemo A, O'Leary ME, Bottaro A. Animal models of rheumatoid pain: experimental systems and insights. *Arthritis research & therapy* 2017;19(1):146. [PubMed: 28666464]
- [76]. Fischer R, Sendetski M, Del Rivero T, Martinez GF, Bracchi-Ricard V, Swanson KA, Pruzinsky EK, Delguercio N, Rosalino MJ, Padutsch T, Kontermann RE, Pfizenmaier K, Bethea JR. TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. *Proceedings of the National Academy of Sciences of the United States of America* 2019;116(34):17045–17050. [PubMed: 31391309]
- [77]. Fitzgerald M The development of nociceptive circuits. *Nat Rev Neurosci* 2005;6(7):507–520. [PubMed: 15995722]
- [78]. Franco-Enzastiga U, Garcia G, Murbartian J, Gonzalez-Barrios R, Salinas-Abarca AB, Sanchez-Hernandez B, Tavares-Ferreira D, Herrera LA, Barragan-Iglesias P, Delgado-Lezama R, Price TJ, Granados-Soto V. Sex-dependent pronociceptive role of spinal alpha5 -GABAA receptor and its epigenetic regulation in neuropathic rodents. *Journal of neurochemistry* 2020.
- [79]. Fried NT, Chamesian A, Zylka MJ, Abdus-Saboor I. Improving pain assessment in mice and rats with advanced videography and computational approaches. *Pain* 2020;161(7):1420–1424. [PubMed: 32102021]
- [80]. Gamaro GD, Torres IL, Laste G, Fontella FU, Silveira PP, Manoli LP, Frantz F, Eickhoff F, Dalmaz C. Gender-dependent effect on nociceptive response induced by chronic variable stress. *Physiology & behavior* 2014;135:44–48. [PubMed: 24907697]
- [81]. Gaumont I, Arsenault P, Marchand S. Specificity of female and male sex hormones on excitatory and inhibitory phases of formalin-induced nociceptive responses. *Brain research* 2005;1052(1):105–111. [PubMed: 16005855]
- [82]. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. *Nature reviews Immunology* 2020;20(2):95–112.
- [83]. Gong WY, Abdelhamid RE, Carvalho CS, Sluka KA. Resident Macrophages in Muscle Contribute to Development of Hyperalgesia in a Mouse Model of Noninflammatory Muscle Pain. *The journal of pain : official journal of the American Pain Society* 2016;17(10):1081–1094.
- [84]. Gorman AL, Yu CG, Ruenes GR, Daniels L, Yezierski RP. Conditions affecting the onset, severity, and progression of a spontaneous pain-like behavior after excitotoxic spinal cord injury. *The journal of pain : official journal of the American Pain Society* 2001;2(4):229–240.
- [85]. Green DP, Limjunyawong N, Gour N, Pundir P, Dong X. A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain. *Neuron* 2019;101(3):412–420 e413. [PubMed: 30686732]
- [86]. Gregory NS, Gibson-Corley K, Frey-Law L, Sluka KA. Fatigue-enhanced hyperalgesia in response to muscle insult: induction and development occur in a sex-dependent manner. *Pain* 2013;154(12):2668–2676. [PubMed: 23906552]
- [87]. Gregus AM, Buczynski MW, Dumlao DS, Norris PC, Rai G, Simeonov A, Maloney DJ, Jadhav A, Xu Q, Wei SC, Fitzsimmons BL, Dennis EA, Yaksh TL. Inhibition of spinal 15-LOX-1 attenuates TLR4-dependent, nonsteroidal anti-inflammatory drug-unresponsive hyperalgesia in male rats. *Pain* 2018;159(12):2620–2629. [PubMed: 30130298]
- [88]. Gregus AM, Doolen S, Dumlao DS, Buczynski MW, Takasusuki T, Fitzsimmons BL, Hua XY, Taylor BK, Dennis EA, Yaksh TL. Spinal 12-lipoxygenase-derived hepoxilin A3 contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors. *Proceedings of the National Academy of Sciences of the United States of America* 2012;109(17):6721–6726. [PubMed: 22493235]
- [89]. Guo TZ, Shi X, Li WW, Wei T, Clark JD, Kingery WS. Sex differences in the temporal development of pronociceptive immune responses in the tibia fracture mouse model. *Pain* 2019;160(9):2013–2027. [PubMed: 31033779]
- [90]. Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, Hohmann AG. Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. *Pain* 2011;152(9):1976–1987. [PubMed: 21550725]

- [91]. Hartlehnert M, Derksen A, Hagenacker T, Kindermann D, Schafers M, Pawlak M, Kieseier BC, Meyer Zu Horste G. Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II. *Scientific reports* 2017;7(1):12518. [PubMed: 28970572]
- [92]. Harton LR, Richardson JR, Armendariz A, Nazarian A. Dissociation of morphine analgesic effects in the sensory and affective components of formalin-induced spontaneous pain in male and female rats. *Brain research* 2017;1658:36–41. [PubMed: 28089665]
- [93]. Hipolito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, Virag L, Whittington R, Comer SD, Carlton SM, Walker BM, Bruchas MR, Moron JA. Inflammatory Pain Promotes Increased Opioid Self-Administration: Role of Dysregulated Ventral Tegmental Area mu Opioid Receptors. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2015;35(35):12217–12231. [PubMed: 26338332]
- [94]. Hodyl NA, Walker FR, Krivanek KM, Clifton VL, Hodgson DM. Prenatal endotoxin exposure alters behavioural pain responses to lipopolysaccharide in adult offspring. *Physiology & behavior* 2010;100(2):143–147. [PubMed: 20184906]
- [95]. Hsieh CT, Lee YJ, Dai X, Ojeda NB, Lee HJ, Tien LT, Fan LW. Systemic Lipopolysaccharide-Induced Pain Sensitivity and Spinal Inflammation Were Reduced by Minocycline in Neonatal Rats. *International journal of molecular sciences* 2018;19(10).
- [96]. Huang T, Lin SH, Malewicz NM, Zhang Y, Zhang Y, Goulding M, LaMotte RH, Ma Q. Identifying the pathways required for coping behaviours associated with sustained pain. *Nature* 2019;565(7737):86–90. [PubMed: 30532001]
- [97]. Inyang KE, Szabo-Pardi T, Wentworth E, McDougal TA, Dussor G, Burton MD, Price TJ. The antidiabetic drug metformin prevents and reverses neuropathic pain and spinal cord microglial activation in male but not female mice. *Pharmacological research* 2019;139:1–16. [PubMed: 30391353]
- [98]. Ji RR, Chamesian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. *Science* 2016;354(6312):572–577. [PubMed: 27811267]
- [99]. Ji Y, Hu B, Li J, Traub RJ. Opposing Roles of Estradiol and Testosterone on Stress-Induced Visceral Hypersensitivity in Rats. *The journal of pain : official journal of the American Pain Society* 2018;19(7):764–776.
- [100]. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2003;23(10):4017–4022. [PubMed: 12764087]
- [101]. Jirkof P, Cesarovic N, Rettich A, Nicholls F, Seifert B, Arras M. Burrowing behavior as an indicator of post-laparotomy pain in mice. *Front Behav Neurosci* 2010;4:165. [PubMed: 21031028]
- [102]. Jirkof P, Fleischmann T, Cesarovic N, Rettich A, Vogel J, Arras M. Assessment of postsurgical distress and pain in laboratory mice by nest complexity scoring. *Laboratory animals* 2013;47(3):153–161. [PubMed: 23563122]
- [103]. Joseph EK, Parada CA, Levine JD. Hyperalgesic priming in the rat demonstrates marked sexual dimorphism. *Pain* 2003;105(1–2):143–150. [PubMed: 14499430]
- [104]. Kandasamy R, Calsbeek JJ, Morgan MM. Home cage wheel running is an objective and clinically relevant method to assess inflammatory pain in male and female rats. *J Neurosci Methods* 2016;263:115–122. [PubMed: 26891874]
- [105]. Kandasamy R, Price TJ. The pharmacology of nociceptor priming. *Handbook of experimental pharmacology* 2015;227:15–37. [PubMed: 25846612]
- [106]. Kehl LJ, Kovacs KJ, Larson AA. Tolerance develops to the effect of lipopolysaccharides on movement-evoked hyperalgesia when administered chronically by a systemic but not an intrathecal route. *Pain* 2004;111(1–2):104–115. [PubMed: 15327814]
- [107]. Kepler KL, Kest B, Kiefel JM, Cooper ML, Bodnar RJ. Roles of gender, gonadectomy and estrous phase in the analgesic effects of intracerebroventricular morphine in rats. *Pharmacology, biochemistry, and behavior* 1989;34(1):119–127.
- [108]. Khoutorsky A, Price TJ. Translational Control Mechanisms in Persistent Pain. *Trends Neurosci* 2018;41(2):100–114. [PubMed: 29249459]



- [109]. King T, Porreca F. Preclinical assessment of pain: improving models in discovery research. *Curr Top Behav Neurosci* 2014;20:101–120. [PubMed: 25012511]
- [110]. Klein SL. Immune cells have sex and so should journal articles. *Endocrinology* 2012;153(6):2544–2550. [PubMed: 22434079]
- [111]. Klinck MP, Mogil JS, Moreau M, Lascelles BDX, Flecknell PA, Poitte T, Troncy E. Translational pain assessment: could natural animal models be the missing link? *Pain* 2017;158(9):1633–1646. [PubMed: 28614187]
- [112]. Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. *Annu Rev Neurosci* 2009;32:149–184. [PubMed: 19555289]
- [113]. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast Cell: A Multi-Functional Master Cell. *Frontiers in immunology* 2015;6:620. [PubMed: 26779180]
- [114]. Krzanowska EK, Ogawa S, Pfaff DW, Bodnar RJ. Reversal of sex differences in morphine analgesia elicited from the ventrolateral periaqueductal gray in rats by neonatal hormone manipulations. *Brain research* 2002;929(1):1–9. [PubMed: 11852025]
- [115]. Kuba T, Wu HB, Nazarian A, Festa ED, Barr GA, Jenab S, Inturrisi CE, Quinones-Jenab V. Estradiol and progesterone differentially regulate formalin-induced nociception in ovariectomized female rats. *Horm Behav* 2006;49(4):441–449. [PubMed: 16257405]
- [116]. LaCroix-Fralish ML, Rutkowski MD, Weinstein JN, Mogil JS, Deleo JA. The magnitude of mechanical allodynia in a rodent model of lumbar radiculopathy is dependent on strain and sex. *Spine* 2005;30(16):1821–1827. [PubMed: 16103850]
- [117]. LaCroix-Fralish ML, Tawfik VL, DeLeo JA. The organizational and activational effects of sex hormones on tactile and thermal hypersensitivity following lumbar nerve root injury in male and female rats. *Pain* 2005;114(1–2):71–80. [PubMed: 15733633]
- [118]. Lacroix-Fralish ML, Tawfik VL, Nutile-McMenemy N, Deleo JA. Neuregulin 1 is a pronociceptive cytokine that is regulated by progesterone in the spinal cord: implications for sex specific pain modulation. *European journal of pain (London, England)* 2008;12(1):94–103.
- [119]. LaCroix-Fralish ML, Tawfik VL, Spratt KF, DeLeo JA. Sex differences in lumbar spinal cord gene expression following experimental lumbar radiculopathy. *Journal of molecular neuroscience : MN* 2006;30(3):283–295. [PubMed: 17401154]
- [120]. Lallemand F, Ernfors P. Molecular interactions underlying the specification of sensory neurons. *Trends Neurosci* 2012;35(6):373–381. [PubMed: 22516617]
- [121]. Lan LS, Ping YJ, Na WL, Miao J, Cheng QQ, Ni MZ, Lei L, Fang LC, Guang RC, Jin Z, Wei L. Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. *Molecular pain* 2010;6:2. [PubMed: 20089147]
- [122]. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *The journal of pain : official journal of the American Pain Society* 2009;10(9):895–926.
- [123]. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. *Nature reviews Immunology* 2015;15(12):731–744.
- [124]. Lawson SN, Fang X, Djouhri L. Nociceptor subtypes and their incidence in rat lumbar dorsal root ganglia (DRGs): focussing on C-polymodal nociceptors, Abeta-nociceptors, moderate pressure receptors and their receptive field depths. *Curr Opin Physiol* 2019;11:125–146. [PubMed: 31956744]
- [125]. Le Pichon CE, Chesler AT. The functional and anatomical dissection of somatosensory subpopulations using mouse genetics. *Front Neuroanat* 2014;8:21. [PubMed: 24795573]
- [126]. Leonelli E, Bianchi R, Cavaletti G, Caruso D, Crippa D, Garcia-Segura LM, Lauria G, Magnaghi V, Roglio I, Melcangi RC. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. *Neuroscience* 2007;144(4):1293–1304. [PubMed: 17187935]
- [127]. Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. *Sci Immunol* 2019;4(33).
- [128]. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nature reviews Immunology* 2018;18(4):225–242.

- [129]. Lima M, Malheiros J, Negrigo A, Tescarollo F, Medeiros M, Suchecki D, Tannus A, Guinsburg R, Covolan L. Sex-related long-term behavioral and hippocampal cellular alterations after nociceptive stimulation throughout postnatal development in rats. *Neuropharmacology* 2014;77:268–276. [PubMed: 24148811]
- [130]. Liu P, Xing B, Chu Z, Liu F, Lei G, Zhu L, Gao Y, Chen T, Dang YH. Dopamine D3 receptor knockout mice exhibit abnormal nociception in a sex-different manner. *Journal of neuroscience research* 2017;95(7):1438–1445. [PubMed: 27716994]
- [131]. Liu SS, Pickens S, Burma NE, Ibarra-Lecue I, Yang H, Xue L, Cook C, Hakimian JK, Severino AL, Lueptow L, Komarek K, Taylor AMW, Olmstead MC, Carroll FI, Bass CE, Andrews AM, Walwyn W, Trang T, Evans CJ, Leslie FM, Cahill CM. Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2019;39(21):4162–4178. [PubMed: 30862664]
- [132]. Long CC, Sadler KE, Kolber BJ. Hormonal and molecular effects of restraint stress on formalin-induced pain-like behavior in male and female mice. *Physiology & behavior* 2016;165:278–285. [PubMed: 27520589]
- [133]. Lopes DM, Malek N, Edye M, Jager SB, McMurray S, McMahan SB, Denk F. Sex differences in peripheral not central immune responses to pain-inducing injury. *Scientific reports* 2017;7(1):16460. [PubMed: 29184144]
- [134]. Loram LC, Sholar PW, Taylor FR, Wiesler JL, Babb JA, Strand KA, Berkelhammer D, Day HE, Maier SF, Watkins LR. Sex and estradiol influence glial pro-inflammatory responses to lipopolysaccharide in rats. *Psychoneuroendocrinology* 2012;37(10):1688–1699. [PubMed: 22497984]
- [135]. Lu JS, Song Q, Zhang MM, Zhuo M. No requirement of interleukin-1 for long-term potentiation in the anterior cingulate cortex of adult mice. *Molecular pain* 2018;14:1744806918765799. [PubMed: 29592781]
- [136]. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. *J Biomed Sci* 2020;27(1):1. [PubMed: 31894001]
- [137]. Luo X, Fitzsimmons B, Mohan A, Zhang L, Terrando N, Kordasiewicz H, Ji RR. Intrathecal administration of antisense oligonucleotide against p38alpha but not p38beta MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice. *Brain, behavior, and immunity* 2018;72:34–44.
- [138]. Malan TP Jr., Porreca F. Lipid mediators regulating pain sensitivity. *Prostaglandins Other Lipid Mediat* 2005;77(1–4):123–130. [PubMed: 16099397]
- [139]. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, Tortorella MD, Mogil JS. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. *Osteoarthritis and cartilage* 2010;18(4):572–580. [PubMed: 20036347]
- [140]. Mannino CA, South SM, Quinones-Jenab V, Inturrisi CE. Estradiol replacement in ovariectomized rats is antihyperalgesic in the formalin test. *The journal of pain : official journal of the American Pain Society* 2007;8(4):334–342.
- [141]. Mapplebeck JC, Beggs S, Salter MW. Sex differences in pain: a tale of two immune cells. *Pain* 2016;157 Suppl 1:S2–6. [PubMed: 26785152]
- [142]. Mapplebeck JCS, Dalgarno R, Tu Y, Moriarty O, Beggs S, Kwok CHT, Halievski K, Assi S, Mogil JS, Trang T, Salter MW. Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. *Pain* 2018;159(9):1752–1763. [PubMed: 29927790]
- [143]. Mapplebeck JCS, Lorenzo LE, Lee KY, Gauthier C, Muley MM, De Koninck Y, Prescott SA, Salter MW. Chloride Dysregulation through Downregulation of KCC2 Mediates Neuropathic Pain in Both Sexes. *Cell reports* 2019;28(3):590–596 e594. [PubMed: 31315039]
- [144]. Marcelo KL, Goldie LC, Hirschi KK. Regulation of endothelial cell differentiation and specification. *Circulation research* 2013;112(9):1272–1287. [PubMed: 23620236]
- [145]. Martin LJ, Acland EL, Cho C, Gandhi W, Chen D, Corley E, Kadoura B, Levy T, Mirali S, Tohyama S, Khan S, MacIntyre LC, Carlson EN, Schweinhardt P, Mogil JS. Male-Specific Conditioned Pain Hypersensitivity in Mice and Humans. *Curr Biol* 2020;30(3):556–559. [PubMed: 32017873]



- [146]. Massaly N, Copits BA, Wilson-Poe AR, Hipolito L, Markovic T, Yoon HJ, Liu S, Walicki MC, Bhatti DL, Sirohi S, Klaas A, Walker BM, Neve R, Cahill CM, Shoghi KI, Gereau RWt, McCall JG, Al-Hasani R, Bruchas MR, Moron JA. Pain-Induced Negative Affect Is Mediated via Recruitment of The Nucleus Accumbens Kappa Opioid System. *Neuron* 2019;102(3):564–573 e566. [PubMed: 30878290]
- [147]. McEwen BS, Kalia M. The role of corticosteroids and stress in chronic pain conditions. *Metabolism: clinical and experimental* 2010;59 Suppl 1:S9–15. [PubMed: 20837196]
- [148]. McMahan SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. *Experimental neurology* 2005;192(2):444–462. [PubMed: 15755561]
- [149]. Megat S, Shiers S, Moy JK, Barragan-Iglesias P, Pradhan G, Seal RP, Dussor G, Price TJ. A Critical Role for Dopamine D5 Receptors in Pain Chronicity in Male Mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2018;38(2):379–397. [PubMed: 29167404]
- [150]. Melzack R, Casey KL. Localized temperature changes evoked in the brain by somatic stimulation. *Experimental neurology* 1967;17(3):276–292. [PubMed: 6019261]
- [151]. Menard C, Pfaul ML, Hodes GE, Russo SJ. Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2017;42(1):62–80. [PubMed: 27291462]
- [152]. Meneses G, Rosetti M, Espinosa A, Florentino A, Bautista M, Diaz G, Olvera G, Barcena B, Fleury A, Adalid-Peralta L, Lamoyi E, Fragoso G, Sciutto E. Recovery from an acute systemic and central LPS-inflammation challenge is affected by mouse sex and genetic background. *PLoS one* 2018;13(8):e0201375. [PubMed: 30133465]
- [153]. Meulders A, Vlaeyen JW. The acquisition and generalization of cued and contextual pain-related fear: an experimental study using a voluntary movement paradigm. *Pain* 2013;154(2):272–282. [PubMed: 23211100]
- [154]. Mifflin KA, Yousuf MS, Thorburn KC, Huang J, Perez-Munoz ME, Tenorio G, Walter J, Ballanyi K, Drohomysky PC, Dunn SE, Kerr BJ. Voluntary wheel running reveals sex-specific nociceptive factors in murine experimental autoimmune encephalomyelitis. *Pain* 2019;160(4):870–881. [PubMed: 30540622]
- [155]. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. *Nat Rev Neurosci* 2009;10(1):23–36. [PubMed: 19096368]
- [156]. Mitchell K, Yang HY, Tessier PA, Muhly WT, Swaim WD, Szalayova I, Keller JM, Mezey E, Iadarola MJ. Localization of S100A8 and S100A9 expressing neutrophils to spinal cord during peripheral tissue inflammation. *Pain* 2008;134(1–2):216–231. [PubMed: 18063312]
- [157]. Mogil JS. Animal models of pain: progress and challenges. *Nat Rev Neurosci* 2009;10(4):283–294. [PubMed: 19259101]
- [158]. Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. *Nat Rev Neurosci* 2012;13(12):859–866. [PubMed: 23165262]
- [159]. Mogil JS. Qualitative sex differences in pain processing: emerging evidence of a biased literature. *Nat Rev Neurosci* 2020;21(7):353–365.
- [160]. Mogil JS, Belknap JK. Sex and genotype determine the selective activation of neurochemically-distinct mechanisms of swim stress-induced analgesia. *Pharmacology, biochemistry, and behavior* 1997;56(1):61–66.
- [161]. Mogil JS, Chesler EJ, Wilson SG, Juraska JM, Sternberg WF. Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype. *Neurosci Biobehav Rev* 2000;24(3):375–389. [PubMed: 10781697]
- [162]. Mogil JS, Pang DSJ, Silva Dutra GG, Chambers CT. The development and use of facial grimace scales for pain measurement in animals. *Neurosci Biobehav Rev* 2020;116:480–493.
- [163]. Monk KR, Feltri ML, Taveggia C. New insights on Schwann cell development. *Glia* 2015;63(8):1376–1393. [PubMed: 25921593]
- [164]. Montilla-Garcia A, Tejada MA, Perazzoli G, Entrena JM, Portillo-Salido E, Fernandez-Segura E, Canizares FJ, Cobos EJ. Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. *Neuropharmacology* 2017;125:231–242. [PubMed: 28760650]

- [165]. Moriarty O, Tu Y, Sengar AS, Salter MW, Beggs S, Walker SM. Priming of Adult Incision Response by Early-Life Injury: Neonatal Microglial Inhibition Has Persistent But Sexually Dimorphic Effects in Adult Rats. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2019;39(16):3081–3093. [PubMed: 30796159]
- [166]. Moy JK, Szabo-Pardi T, Tillu DV, Megat S, Pradhan G, Kume M, Asiedu MN, Burton MD, Dussor G, Price TJ. Temporal and sex differences in the role of BDNF/TrkB signaling in hyperalgesic priming in mice and rats. *Neurobiol Pain* 2019;5:100024. [PubMed: 31194015]
- [167]. Mullard A 2019 FDA drug approvals. *Nat Rev Drug Discov* 2020;19(2):79–84. [PubMed: 32020068]
- [168]. Nalbandian G, Kovats S. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. *Immunologic research* 2005;31(2):91–106. [PubMed: 15778508]
- [169]. Navratilova E, Porreca F. Reward and motivation in pain and pain relief. *Nature neuroscience* 2014;17(10):1304–1312. [PubMed: 25254980]
- [170]. Navratilova E, Xie JY, King T, Porreca F. Evaluation of reward from pain relief. *Annals of the New York Academy of Sciences* 2013;1282:1–11. [PubMed: 23496247]
- [171]. Negus SS. Core Outcome Measures in Preclinical Assessment of Candidate Analgesics. *Pharmacol Rev* 2019;71(2):225–266. [PubMed: 30898855]
- [172]. Ng LG, Ostuni R, Hidalgo A. Heterogeneity of neutrophils. *Nature reviews Immunology* 2019;19(4):255–265.
- [173]. Nieto FR, Clark AK, Grist J, Hathway GJ, Chapman V, Malcangio M. Neuron-immune mechanisms contribute to pain in early stages of arthritis. *Journal of neuroinflammation* 2016;13(1):96. [PubMed: 27130316]
- [174]. O'Brien MS, Philpott HTA, McDougall JJ. Targeting the Nav1.8 ion channel engenders sex-specific responses in lysophosphatidic acid-induced joint neuropathy. *Pain* 2019;160(1):269–278. [PubMed: 30211781]
- [175]. Odem MA, Bavencoffe AG, Cassidy RM, Lopez ER, Tian J, Dessauer CW, Walters ET. Isolated nociceptors reveal multiple specializations for generating irregular ongoing activity associated with ongoing pain. *Pain* 2018;159(11):2347–2362. [PubMed: 30015712]
- [176]. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. *The Journal of clinical investigation* 2010;120(11):3779–3787. [PubMed: 21041960]
- [177]. Paller CJ, Campbell CM, Edwards RR, Dobs AS. Sex-based differences in pain perception and treatment. *Pain medicine (Malden, Mass)* 2009;10(2):289–299.
- [178]. Patil M, Belugin S, Mecklenburg J, Wangzhou A, Paige C, Barba-Escobedo PA, Boyd JT, Goffin V, Grattan D, Boehm U, Dussor G, Price TJ, Akopian AN. Prolactin Regulates Pain Responses via a Female-Selective Nociceptor-Specific Mechanism. *iScience* 2019;20:449–465. [PubMed: 31627131]
- [179]. Peng J, Gu N, Zhou L, U BE, Murugan M, Gan WB, Wu LJ. Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury. *Nature communications* 2016;7:12029.
- [180]. Perl ER. Cutaneous polymodal receptors: characteristics and plasticity. *Prog Brain Res* 1996;113:21–37. [PubMed: 9009726]
- [181]. Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z. Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. *Neuroscience* 2009;159(4):1216–1232. [PubMed: 19409213]
- [182]. Posillico CK, Terasaki LS, Bilbo SD, Schwarz JM. Examination of sex and minocycline treatment on acute morphine-induced analgesia and inflammatory gene expression along the pain pathway in Sprague-Dawley rats. *Biology of sex differences* 2015;6:33. [PubMed: 26693004]
- [183]. Price TJ, Basbaum AI, Bresnahan J, Chambers JF, De Koninck Y, Edwards RR, Ji RR, Katz J, Kavelaars A, Levine JD, Porter L, Schechter N, Sluka KA, Terman GW, Wager TD, Yaksh TL, Dworkin RH. Transition to chronic pain: opportunities for novel therapeutics. *Nat Rev Neurosci* 2018;19(7):383–384. [PubMed: 29765159]


- [184]. Prusator DK, Greenwood-Van Meerveld B. Amygdala-mediated mechanisms regulate visceral hypersensitivity in adult females following early life stress: importance of the glucocorticoid receptor and corticotropin-releasing factor. *Pain* 2017;158(2):296–305. [PubMed: 27849648]
- [185]. Rahn EJ, Iannitti T, Donahue RR, Taylor BK. Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus. *Biology of sex differences* 2014;5(1):4. [PubMed: 24581045]
- [186]. Rainville JR, Hodes GE. Inflaming sex differences in mood disorders. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2019;44(1):184–199. [PubMed: 29955150]
- [187]. Rainville JR, Tsyglakova M, Hodes GE. Deciphering sex differences in the immune system and depression. *Frontiers in neuroendocrinology* 2018;50:67–90. [PubMed: 29288680]
- [188]. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 2020.
- [189]. Ren K, Wei F, Dubner R, Murphy A, Hoffman GE. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: involvement of spinal NMDA receptor mechanisms. *Brain research* 2000;865(2):272–277. [PubMed: 10821931]
- [190]. Richardson WD, Kessaris N, Pringle N. Oligodendrocyte wars. *Nat Rev Neurosci* 2006;7(1):11–18. [PubMed: 16371946]
- [191]. Rosen S, Ham B, Mogil JS. Sex differences in neuroimmunity and pain. *Journal of neuroscience research* 2017;95(1–2):500–508. [PubMed: 27870397]
- [192]. Rosen SF, Ham B, Drouin S, Boachie N, Chabot-Dore AJ, Austin JS, Diatchenko L, Mogil JS. T-Cell Mediation of Pregnancy Analgesia Affecting Chronic Pain in Mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2017;37(41):9819–9827. [PubMed: 28877966]
- [193]. Rosen SF, Ham B, Haichin M, Walters IC, Tohyama S, Sotocinal SG, Mogil JS. Increased pain sensitivity and decreased opioid analgesia in T-cell-deficient mice and implications for sex differences. *Pain* 2019;160(2):358–366. [PubMed: 30335680]
- [194]. Ruau D, Liu LY, Clark JD, Angst MS, Butte AJ. Sex differences in reported pain across 11,000 patients captured in electronic medical records. *The journal of pain : official journal of the American Pain Society* 2012;13(3):228–234.
- [195]. Rudjito R, Agalave NM, Farinotti AB, Lundback P, Szabo-Pardi T, Price TJ, Harris HE, Burton MD, Svensson CI. Sex- and cell-dependent contribution of peripheral HMGB1 and TLR4 in arthritis-induced pain. *Pain* 2020.
- [196]. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. *Physiological reviews* 2009;89(2):707–758. [PubMed: 19342617]
- [197]. Scheff NN, Bhattacharya A, Dowse E, Dang RX, Dolan JC, Wang S, Kim H, Albertson DG, Schmidt BL. Neutrophil-Mediated Endogenous Analgesia Contributes to Sex Differences in Oral Cancer Pain. *Frontiers in integrative neuroscience* 2018;12:52. [PubMed: 30405367]
- [198]. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. *Nature neuroscience* 2007;10(11):1361–1368. [PubMed: 17965656]
- [199]. Shepherd AJ, Copits BA, Mickle AD, Karlsson P, Kadunganattil S, Haroutounian S, Tadinada SM, de Kloet AD, Valtcheva MV, McIlvried LA, Sheahan TD, Jain S, Ray PR, Usachev YM, Dussor G, Krause EG, Price TJ, Gereau RWt, Mohapatra DP. Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2018;38(32):7032–7057. [PubMed: 29976627]
- [200]. Shi Y, Shu J, Liang Z, Yuan S, Tang SJ. EXPRESS: Oligodendrocytes in HIV-associated pain pathogenesis. *Molecular pain* 2016;12.
- [201]. Shukla R, Henkel ND, Alganem K, Hamoud AR, Reigle J, Alnafisah RS, Eby HM, Imami AS, Creeden JF, Miruzzi SA, Meller J, McCullumsmith RE. Signature-based approaches for informed drug repurposing: targeting CNS disorders. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2020.

- [202]. Sikandar S, Minett MS, Millet Q, Santana-Varela S, Lau J, Wood JN, Zhao J. Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain. *Brain : a journal of neurology* 2018;141(4):1028–1039. [PubMed: 29394316]
- [203]. Sloan SA, Barres BA. Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders. *Curr Opin Neurobiol* 2014;27:75–81. [PubMed: 24694749]
- [204]. Sofroniew MV. Astrocyte Reactivity: Subtypes, States, and Functions in CNS Innate Immunity. *Trends Immunol* 2020.
- [205]. Sorge RE, LaCroix-Fralish ML, Tuttle AH, Sotocinal SG, Austin JS, Ritchie J, Chanda ML, Graham AC, Topham L, Beggs S, Salter MW, Mogil JS. Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2011;31(43):15450–15454. [PubMed: 22031891]
- [206]. Sorge RE, Mapplebeck JC, Rosen S, Beggs S, Taves S, Alexander JK, Martin LJ, Austin JS, Sotocinal SG, Chen D, Yang M, Shi XQ, Huang H, Pillon NJ, Bilan PJ, Tu Y, Klip A, Ji RR, Zhang J, Salter MW, Mogil JS. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. *Nature neuroscience* 2015;18(8):1081–1083. [PubMed: 26120961]
- [207]. Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, Wieskopf JS, Acland EL, Dokova A, Kadoura B, Leger P, Mapplebeck JC, McPhail M, Delaney A, Wigerblad G, Schumann AP, Quinn T, Frasnelli J, Svensson CI, Sternberg WF, Mogil JS. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. *Nat Methods* 2014;11(6):629–632. [PubMed: 24776635]
- [208]. Sorge RE, Totsch SK. Sex Differences in Pain. *Journal of neuroscience research* 2017;95(6):1271–1281. [PubMed: 27452349]
- [209]. Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, Mapplebeck JC, Wei P, Zhan S, Zhang S, McDougall JJ, King OD, Mogil JS. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. *Molecular pain* 2011;7:55. [PubMed: 21801409]
- [210]. Stokes JA, Cheung J, Eddinger K, Corr M, Yaksh TL. Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice. *Journal of neuroinflammation* 2013;10:148. [PubMed: 24321498]
- [211]. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. *Neuroscience* 2001;103(2):529–539. [PubMed: 11246166]
- [212]. Taiwo OB, Kovacs KJ, Sun Y, Larson AA. Unilateral spinal nerve ligation leads to an asymmetrical distribution of mast cells in the thalamus of female but not male mice. *Pain* 2005;114(1–2):131–140. [PubMed: 15733638]
- [213]. Tajerian M, Sahbaie P, Sun Y, Leu D, Yang HY, Li W, Huang TT, Kingery W, David Clark J. Sex differences in a Murine Model of Complex Regional Pain Syndrome. *Neurobiology of learning and memory* 2015;123:100–109. [PubMed: 26070658]
- [214]. Tall JM, Crisp T. Effects of gender and gonadal hormones on nociceptive responses to intraplantar carrageenan in the rat. *Neuroscience letters* 2004;354(3):239–241. [PubMed: 14700740]
- [215]. Tappe-Theodor A, King T, Morgan MM. Pros and Cons of Clinically Relevant Methods to Assess Pain in Rodents. *Neurosci Biobehav Rev* 2019;100:335–343. [PubMed: 30885811]
- [216]. Taves S, Berta T, Liu DL, Gan S, Chen G, Kim YH, Van de Ven T, Laufer S, Ji RR. Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. *Brain, behavior, and immunity* 2016;55:70–81.
- [217]. Teixeira JM, Bobinski F, Parada CA, Sluka KA, Tambeli CH. P2X3 and P2X2/3 Receptors Play a Crucial Role in Articular Hyperalgesia Development Through Inflammatory Mechanisms in the Knee Joint Experimental Synovitis. *Molecular neurobiology* 2017;54(8):6174–6186. [PubMed: 27709491]
- [218]. Teixeira JM, Dias EV, Parada CA, Tambeli CH. Intra-Articular Blockade of P2X7 Receptor Reduces the Articular Hyperalgesia and Inflammation in the Knee Joint Synovitis Especially in

- Female Rats. *The journal of pain : official journal of the American Pain Society* 2017;18(2):132–143.
- [219]. Turner JM, Lomas LM, Picker MJ. Influence of estrous cycle and gonadal hormone depletion on nociception and opioid antinociception in female rats of four strains. *The journal of pain : official journal of the American Pain Society* 2005;6(6):372–383.
- [220]. Thakur M, Crow M, Richards N, Davey GI, Levine E, Kelleher JH, Agle CC, Denk F, Harridge SD, McMahon SB. Defining the nociceptor transcriptome. *Front Mol Neurosci* 2014;7:87. [PubMed: 25426020]
- [221]. Toma W, Kyte SL, Bagdas D, Alkhlaif Y, Alsharari SD, Lichtman AH, Chen ZJ, Del Fabbro E, Bigbee JW, Gewirtz DA, Damaj MI. Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. *Neuropharmacology* 2017;117:305–315. [PubMed: 28237807]
- [222]. Tonsfeldt KJ, Suchland KL, Beeson KA, Lowe JD, Li MH, Ingram SL. Sex Differences in GABAA Signaling in the Periaqueductal Gray Induced by Persistent Inflammation. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2016;36(5):1669–1681. [PubMed: 26843648]
- [223]. Treede RD. Gain control mechanisms in the nociceptive system. *Pain* 2016;157(6):1199–1204. [PubMed: 26817644]
- [224]. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. *Nature* 2003;424(6950):778–783. [PubMed: 12917686]
- [225]. Usoskin D, Furlan A, Islam S, Abdo H, Lonnerberg P, Lou D, Hjerling-Leffler J, Haeggstrom J, Kharchenko O, Kharchenko PV, Linnarsson S, Ernfors P. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. *Nature neuroscience* 2015;18(1):145–153. [PubMed: 25420068]
- [226]. Vacca V, Marinelli S, Pieroni L, Urbani A, Luvisetto S, Pavone F. Higher pain perception and lack of recovery from neuropathic pain in females: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. *Pain* 2014;155(2):388–402. [PubMed: 24231652]
- [227]. Vacca V, Marinelli S, Pieroni L, Urbani A, Luvisetto S, Pavone F. 17beta-estradiol counteracts neuropathic pain: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. *Scientific reports* 2016;6:18980. [PubMed: 26742647]
- [228]. Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. *The journal of pain : official journal of the American Pain Society* 2016;17(9 Suppl):T50–69.
- [229]. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, Brusadelli A, Viviani B, Ciana P, Maggi A. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2001;21(6):1809–1818. [PubMed: 11245665]
- [230]. Vendruscolo LF, Pamplona FA, Takahashi RN. Strain and sex differences in the expression of nociceptive behavior and stress-induced analgesia in rats. *Brain research* 2004;1030(2):277–283. [PubMed: 15571676]
- [231]. Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, Joslyn CM, Liu QS, Tomarchio AJ, Lichtman AH, Selley DE, Sim-Selley LJ, Cravatt BF. Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action. *Cell reports* 2015;12(5):798–808. [PubMed: 26212325]
- [232]. Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello E, Sironi L, Vegeto E, Maggi A. Sex-Specific Features of Microglia from Adult Mice. *Cell reports* 2018;23(12):3501–3511. [PubMed: 29924994]
- [233]. Villa A, Rizzi N, Vegeto E, Ciana P, Maggi A. Estrogen accelerates the resolution of inflammation in macrophagic cells. *Scientific reports* 2015;5:15224. [PubMed: 26477569]
- [234]. Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. *Mediators of inflammation* 2013;2013:183041. [PubMed: 23606790]
- [235]. Whiteside GT, Pomonis JD, Kennedy JD. An industry perspective on the role and utility of animal models of pain in drug discovery. *Neuroscience letters* 2013;557 Pt A:65–72. [PubMed: 23994390]




- [236]. Wilkerson JL, Donvito G, Grim TW, Abdullah RA, Ogasawara D, Cravatt BF, Lichtman AH. Investigation of Diacylglycerol Lipase Alpha Inhibition in the Mouse Lipopolysaccharide Inflammatory Pain Model. *The Journal of pharmacology and experimental therapeutics* 2017;363(3):394–401. [PubMed: 28970359]
- [237]. Wilkerson JL, Ghosh S, Bagdas D, Mason BL, Crowe MS, Hsu KL, Wise LE, Kinsey SG, Damaj MI, Cravatt BF, Lichtman AH. Diacylglycerol lipase beta inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. *British journal of pharmacology* 2016;173(10):1678–1692. [PubMed: 26915789]
- [238]. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. *J Clin Neurophysiol* 1997;14(1):2–31. [PubMed: 9013357]
- [239]. Witkin LR, Zylberger D, Mehta N, Hindenlang M, Johnson C, Kean J, Horn SD, Inturrisi CE. Patient-Reported Outcomes and Opioid Use in Outpatients With Chronic Pain. *The journal of pain : official journal of the American Pain Society* 2017;18(5):583–596.
- [240]. Woller SA, Corr M, Yaksh TL. Differences in cisplatin-induced mechanical allodynia in male and female mice. *European journal of pain (London, England)* 2015;19(10):1476–1485.
- [241]. Woller SA, Eddinger KA, Corr M, Yaksh TL. An overview of pathways encoding nociception. *Clinical and experimental rheumatology* 2017;35 Suppl 107(5):40–46.
- [242]. Woller SA, Ocheltree C, Wong SY, Bui A, Fujita Y, Goncalves Dos Santos G, Yaksh TL, Corr M. Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice. *Brain, behavior, and immunity* 2019;76:151–158.
- [243]. Woller SA, Ravula SB, Tucci FC, Beaton G, Corr M, Isseroff RR, Soulika AM, Chigbrow M, Eddinger KA, Yaksh TL. Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state. *Brain, behavior, and immunity* 2016;56:271–280.
- [244]. Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, Sandkuhler J. Central nervous system mast cells in peripheral inflammatory nociception. *Molecular pain* 2011;7:42. [PubMed: 21639869]
- [245]. Xu XJ, Hao JX, Andell-Jonsson S, Poli V, Bartfai T, Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. *Cytokine* 1997;9(12):1028–1033. [PubMed: 9417815]
- [246]. Yan S, Kentner AC. Mechanical allodynia corresponds to Oprm1 downregulation within the descending pain network of male and female rats exposed to neonatal immune challenge. *Brain, behavior, and immunity* 2017;63:148–159.
- [247]. Zarpelon AC, Rodrigues FC, Lopes AH, Souza GR, Carvalho TT, Pinto LG, Xu D, Ferreira SH, Alves-Filho JC, McInnes IB, Ryffel B, Quesniaux VF, Reverchon F, Mortaud S, Menuet A, Liew FY, Cunha FQ, Cunha TM, Verri WA Jr. Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2016;30(1):54–65. [PubMed: 26310268]
- [248]. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. *Brain, behavior, and immunity* 2007;21(5):642–651.



**Figure 1. Nociceptive sensory primary afferent pathways.**


Nociceptors specialized for detection of high-intensity mechanical, thermal and/or chemical stimuli originate in the sensory ganglia (dorsal root, trigeminal and nodose) of the peripheral nervous system generally possess small- to medium-diameter, thinly myelinated **A $\delta$  fibers** or small-diameter unmyelinated **C fibers** and terminate predominantly in spinal superficial laminae I, II and V of the dorsal horn [180; 238]. Nociceptors can be described using the following categories: **Red**, Neurofilament H (NFH)+ **A $\beta$**  large, high threshold mechanoreceptor (HTMR)/heat; **Orange**, peptidergic **A $\delta$**  small/medium, HTMR/heat; **Green**, nonpeptidergic **C** small, HTMR/itch/chemical; **Blue**, peptidergic or nonpeptidergic **C** small polymodal or mechanoheat/cold; **Purple**, peptidergic **A $\delta$**  small/medium HTMR or **C** small polymodal. In recent years, several subclassifications of nociceptors have been proposed, and the reader is directed to several excellent references for more detailed information on evolving designations of primary afferent sensory neuron subtypes: [48; 63; 120; 124; 125; 175; 220; 225].





**Figure 2. Supraspinal nociceptive circuits.**

Nociceptive information transmitted via the **spinal cord dorsal horn** is communicated to the brain along several ascending pathways (merged together in black). Laterally projecting systems to the somatosensory (SSC) and insular cortices (IC) correspond to the classical somatosensory pathway, with a highly preserved body image mapped at several synaptic links. This tract mediates the **sensory/discriminative (red)** component of the pain phenotype. In contrast, medially projecting systems underlying the **ffective (green)** and **motivational (purple)** aspects of pain have relatively crude somatosensory mapping and project to limbic structures appreciated for their roles in emotional responses such as the parabrachial nucleus (PBN), amygdala (AMYG), anterior cingulate cortex (ACC), nucleus accumbens (NAcc) and ventral tegmental area (VTA) [5; 33; 48; 150]. **Cognitive (blue)** interpretation of nociceptive information is mediated by the ACC, prefrontal cortex (PFC), and NAcc. Together, these structures contribute to pain processing by integrating information about its sensory, cognitive and affective/motivational components. The activity of ascending pathways is in turn regulated by descending facilitatory and inhibitory systems, which send projections down to the spinal cord mainly from the ACC or periaqueductal gray (PAG) by way of serotonergic neurons of the nucleus raphe magnus in the rostroventral medulla (MED) or via noradrenergic neurons in the locus coeruleus to modulate excitability of dorsal horn neurons [176].



**Figure 3. Immune and glial cells linked to sex differences in pain hypersensitivity.**

Neuroimmune cells are generally derived from four different progenitor stem cell types (**Blue circles**): **N**, Neuroepithelial [112]; **D**, Mesodermal [72]; **M**, Myeloid [7]; **L**, Lymphoid [6]. Neuroepithelial cells can differentiate into Astrocytes [203; 204], Oligodendrocytes [190], or Schwann Cells [163]. Mesodermal cells can be programmed into Endothelial Cells [144]. Myeloid-derived cells include Microglia [128], Macrophages [123], Neutrophils [172], or Mast Cells [113] and are referred to as Splenocytes [127] (circled in **purple**). Lymphoid cells differentiate into B-Cells [4] and T-Cells [65], and collectively these cells are referred to as Lymphocytes (circled in **green**).

**Table 1.** Rodent models exhibit sex-dependent differences in neuroimmune-mediated pain hypersensitivity

Sex	Model	Pain / Nociception	Rodent	REF
Females	Nerve Injury (SNI)	Tactile allodynia, withdrawal frequency	C57BL/6 mice	24
	Nerve Injury (SNL)	Tactile and cold allodynia	C57BL/6, SWR/J mice; Wistar rats	32, 210, 212
	Nerve Injury (CCI)	Tactile allodynia	CD-1 mice	226, 227
	Nerve Injury (L5 radiculopathy)	Tactile allodynia	Sprague Dawley, Long Evans rats	116
	Nerve injury (SNT)	Tactile allodynia	Sprague Dawley rats	57
	Nerve injury (pSNL)	Tactile allodynia	Sprague Dawley rats	51
	Systemic bacteremia (IP LPS)	Grip force	SWR/J mice	106
	Spinal TLR4 activation (IT LPS)	Grip force	SWR/J mice	106
	Serum-transfer arthritis (K/BxN)	Grip force	C57BL/6 mice	22
	Complete Freund's Adjuvant (CEA)	Tactile allodynia	Lewis rats	46
	Fatigue-enhanced muscle insult	Muscle hyperalgesia	C57BL/6 mice	86
	Joint neuropathy (IA LPA)	Tactile allodynia	Wistar rats	174
	Femoral Bone Cancer	Limb use	Balb/c mice	64
	Complex Regional Pain Syndrome (CRPS)	Tactile allodynia	C57BL/6 mice	213
	Migraine (IC CGRP)	Tactile allodynia, Grimace	CD-1 mice; Sprague Dawley rats;	10
	Multiple Sclerosis (EAE)	Tactile and cold allodynia	C57BL/6 mice	185
	Autoimmune Demyelination	Tactile allodynia	C57BL/6 mice	40
Males	Complete Freund's Adjuvant (CEA)	Tactile allodynia	Sprague Dawley rats	26
	Nerve injury (SNI)	Tactile allodynia	CD-1, C57BL/6 mice	97,205,206
	Context-dependent pain hypersensitivity	Tactile allodynia	CD-1 mice	145,207
	Osteoarthritis (DMM)	Tactile allodynia	CD-1, C57BL/6 mice	139
	Spinal TLR4 activation (IT LPS)	Tactile allodynia	CD-1, C57BL/6 mice	205,206,243
	Serum-transfer arthritis (K/BxN)	Tactile allodynia	C57BL/6J mice	242

**Table 2.**

Sex-dependent cellular and molecular neuroimmune mechanisms driving pain hypersensitivity

Sex	Model	Cell Type(s)	Mediator	Rodent	REF
Females	Nerve injury (CCI)	Schwann cells	MHC-II activation of helper Th-cells	129/FVB mice	91
		Microglia, Astrocytes	Phospho-P38 MAPK in spinal cord	CD-1 mice	226,227
	Nerve injury (SNI)	T-cells	CD4+ and CD8+ T-cell infiltration into lumbar spinal dorsal horn	CD-1 mice	206
	Nerve injury (SNL)	Mast cells	Increased mast cell infiltration into lumbar spinal dorsal horn	SWR/J mice	212
	Nerve Injury (pSNL)	T-cells	Not specified; T-cell infiltration into DRG	Sprague Dawley rats	49,133
	Nerve Injury (L5 radiculopathy)	Not specified	Spinal NRG1, ErbB4, and TAC1; Progesterone	Sprague Dawley rats	118,119
	Femoral bone cancer	Microglia; Not specified	TLR4, CD11b, CD14; Not specified	Balb/c mice; Sprague Dawley rats	64,121
	Migraine (IC nitroglycerin)	Mast cells, Endothelial cells	P2X3	Sprague Dawley rats	71
	Migraine (IC CGRP with priming)	Not specified	RAMP1, CLR, RCP	ICR mice; Sprague Dawley rats	10
	Fatigue-enhanced muscle insult	Lymphocytes	Lymphocyte migration to muscle	C57BL/6 mice	86
	Autoimmune Demyelination (IA MBP)	T-cells	T-cell migration into DRG and spinal cord; PLC in females	C57BL/6 mice	40
	Males	Nerve injury (SNT)	Microglia	CD40+ spinal microglia interaction with infiltrating CD4+ T-cells	Balb/c mice
Nerve injury (SNI)		T-cells	CD2+ cell migration into ipsilateral spinal dorsal horn; Th1-mediated	Sprague Dawley rats	49
			CD4+/CD8+ cell infiltration into ipsilateral spinal cord	C57BL/6 mice	44
		Neurons	TRPV1	C57BL/6 mice	44
		Microglia, Macrophages	TLR4, P2X4, BDNF, Phospho-P38 MAPK	CD-1, C57BL/6 mice; Sprague Dawley rats	142,205,206
Nerve injury (SNL)		Microglia, Neurons	P2X4, Phospho-P38 MAPK	Sprague Dawley, Wistar rats	100,224
Oral cancer		Neutrophils	Ly6G+ neutrophil migration to tumor	C57BL6 mice	197
IPLT carrageenan		Neutrophils; Not specified	S100A8+ and S100A9+ neutrophil migration to spinal vasculature; gonadal hormones	Sprague Dawley, Fischer 344 FBNF1 rats	156,214
Spinal TLR4 activation (IT dsHMGB1)		Microglia, Macrophages	Spinal TNF, IL-1b, CCL2, CxCl1, CxCl2, Gfap, CD11b, females recover faster	C57BL/6 mice	2,3
Spinal TLR4 activation (IT LPS)	Not specified	Spinal TLR4	CD-1, C3H/HEK, C3H/HeN, C57BL/6J, C57BL/10ScNJ, C57BL/10ScSnj mice	205,243	

Sex	Model	Cell Type(s)	Mediator	Rodent	REF
	Serum-transfer arthritis (K/BxN)	Glia	Spinal TLR4 and TNF $\alpha$ , spinal TRPV1	C57BL/6 mice	22,242
	Chemotherapy-induced Peripheral Neuropathy	Not specified	Spinal TLR4, females recover faster	C57BL/6 mice	240

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3.** Sex-independent cellular and molecular neuroimmune mechanisms driving pain hypersensitivity

Model	Cell Type(s)	Mediator	Rodent	REF
Nerve injury (SNT)	Spinal glia	Spinal soluble TNF and IL-1b	Holzman rats	211
	Not specified	IL-6; allodynia F = M; autotomy behavior F > M	C57BL/6 × 129/BV/SV mice	245
	Microglia	CXCR1+ microglia	C57BL/6 mice	179
Nerve injury (CCI)	T-cells	Cd4+ T-cell infiltration into ipsilateral spinal cord	Balb/c mice	34,36
		Phospho-P38 MAPK in males	Balb/c mice	35
	Microglia	CXCR1+ microglia	CD-1 mice; Sprague Dawley rats	216
		P2X4+ microglia	Sprague Dawley rats	216, 248
Nerve injury (SNI)	Macrophages	TNFR1-induced NMDA1 activation in spinal cord, cortex	CD-1 mice; Sprague Dawley rats	142
		CD68, Cd11b+ macrophages; tactile allodynia F = M	C57BL/6 mice	56
	T-cells	TNFR2 essential for recovery	C57BL/6 mice	44
			C57BL/6 mice	76
Nerve injury (pSNL)	Microglia	P2X7	Sprague Dawley rats	54
	Not specified	P2X7	C57BL/6 mice	41
Postoperative pain	DRG neurons	PRLR in females	C57BL/6, 129 mice; Sprague Dawley rats	178
	Microglia	Phospho-P38 MAPK in males	Sprague Dawley rats	165
	Macrophage, Mast cells, Neutrophils,	NLRP3-dependent IL-1b release in DRG and peri-incisional skin in males; NLRP3-independent in females	C57BL/6j, C57BL/6N/129 mice	50
	Mast cells	Mrgprb2	C57BL/6 mice	85
Complex regional pain syndrome (CRPS)	Microglia (males), T-cells (females), B-cells (both)	Spinal IL-6, NK1 in males; delayed adaptive immune response in females	C57BL/6J mice	89
	Not specified	TLR2	CD-1 mice	205
IPLT Zymosan	Neurons	High-affinity tonic GABAA current in PAG	Sprague Dawley rats	222
IPLT CFA	Not specified	Spinal TLR4, serum, TNFa, IL-1b, and IL-6 in males	CD-1 mice; Sprague Dawley rats	26,205
	Glia, Neurons (males); T-cells (females)	DRD1, DRD3 in females; DRD4 in males; BDNF, TLR4 in both sexes	CD-1, C57BL/6J, C57BL/6/129.P2 mice	130,149,193 202,243
Muscle Hyperalgesia	Macrophages	P2X4+ resident macrophages, TLR4, IL-6	C57BL/6 mice	83



Model	Cell Type(s)	Mediator	Rodent	REF
IPLT TNFa	Not specified	Peripheral TRPA1, central TRPV1; mixed males and females	C57BL/6J,129.SvJ, CD-1 mice	66
IPLT Angiotensin II	Macrophages, Neurons	AT2R in skin macrophages transactivates TRPA1 in neurons	C57BL/6J, FVB/NJ mice	199
Hyperalgesic Priming	Neurons	Spinal DRD5 in males; DRG PRLR in females	C57BL/6J,129, C57BL/6J mice	149,178
IT BDNF	Microglia	Spinal KCC2 downregulation	CD-1 mice	143
IT NRG-1	Astrocytes, Neurons	Spinal ErbB	Sprague Dawley rats	118
IT LPS	Not specified	Spinal TLR4	SWR/J mice	106
ICV LPS	Not specified	TLR4	CD-1 mice	205
Intra-PAG LPS	Microglia	TLR4	Sprague Dawley rats	61
IPLT LPS	Not specified	TLR4	CD-1 mice	205
Systemic Bacteremia (IP LPS, neonatal)	Microglia, Not specified	Spinal TLR4, Spinal COX2; Downregulation of Oprm1 in PAG, PFC	Sprague Dawley rats	21,95,246
Migraine (Intracisternal IL-6)	Not specified	BDNF	Sprague Dawley rats	30
IA Carrageenan	Immune cells (in joint)	P2X2 and P2X3 in both sexes; P2X7 in females	Wistar rats	217,218
IA CFA	Not specified	TRPA1, TRPV1, TNFa	CD-1, C57BL/6J mice	66
Collagen antibody-induced arthritis (CAIA)	Glia, Neurons (spinal); Macrophages	Macrophage HMGB1/TLR4 in males; Nociceptor TLR4 in females	Balb/c mice	2,67,195